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ABSTRACT 
SHYH-DAR LI: Targeted Delivery of siRNA to the Tumor 
(Under the direction of Leaf Huang, Ph.D.) 
We have developed a surface-modified LPD (liposome-polycation-DNA) nanoparticle 
formulation by mixing cationic liposomes, a polycationic peptide and nucleic acids (mixture 
of DNA and siRNA) at a fixed ratio, followed by post-inserting a PEGylated lipid.  This self-
assembled nanoparticle formulation was around 100 nm in diameter with 90% encapsulation 
efficiency for siRNA.  The nucleic acid was complexed with the peptide into a compact core, 
which was coated with two lipid bilayers.  The inner lipid bilayer was stabilized by the 
charge-charge interaction between the cationic lipids and the compact core.  Upon addition of 
a PEGylated lipid, the outer lipid bilayer was stripped off and the lipid anchor was inserted 
into the outer leaflet of the inner bilayer, resulting in approximately 10.6 mol% modification 
of PEG (polyethylene glycol) on the surface of the nanoparticles.  The high degree of 
PEGylation completely shielded the charge of the nanoparticles with the zeta potential close 
to neutral (-5.6 ± 4.5 mV) and abolished the reticuloendothelial uptake in the isolated liver. 
When i.v. injected into tumor bearing mice (s.c. human lung cancer xenograft model 
in the nude mice), the nanoparticles delivered 70-80% injected siRNA/g into the tumor, 
while the normal organs only showed a moderate uptake (10-20% injected siRNA/g).  After 
the conjugation of a targeting ligand, anisamide, at the distal end of the PEG, the intracellular 
delivery of siRNA into the sigma receptor expressing tumor was significantly enhanced.  
This led to efficient EGFR silencing, significant apoptosis induction and tumor growth 
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inhibition at the dose of 1.2 mg siRNA/kg for three consecutive injections.  The experimental 
murine lung metastasis model was established by i.v. injecting the mouse melanoma cells, 
which were stably transduced with a luciferase gene by retrovirus, into the mice.  An 
improved metastatic tumor delivery of siRNA was discovered by using the nanoparticles.  
When combinatorial siRNA sequences were delivered, the oncogenes (MDM2, c-myc and 
VEGF) in the lung metastasis were silenced simultaneously, leading to 70-80% tumor load 
reduction and 30% prolongation in animal lifespan.  The nanoparticle formulation showed 
minimal to no otoxicity in both animal models.  The results promise the potential use of this 
formulation clinically. 
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1.0  INTRODUCTION 
siRNA has been called “one of the most exciting discoveries in biology in the last couple of 
years” [1]. With a specific sequence, siRNA (21-23 nucleotides) can selectively inhibit gene 
expression by base-pairing to complementary mRNA transcribed from the target gene. This 
complex drives the formation of the RNA induced silencing complex (RISC) which digests 
the target mRNA and uses the anti-sense strand of the siRNA as a template to seek and 
destroy all copies of the target mRNA [1]. RNAi has quickly become one of the most 
powerful and indispensable tools in molecular biology. By targeting to the mRNA that 
encodes for a disease-associated protein, siRNA is also currently being applied as a 
therapeutic agent in antiviral therapy, neurological diseases, and cancer therapy [1].  
However, siRNA is vulnerable to nuclease degradation and cannot pass through membrane 
barriers due to its hydrophilic nucleic acid backbone.  Delivery of siRNA has thus become 
one of the major research focuses in the RNAi field since 2004 and the progress of which 
before 2007 has been reviewed by Kim and Rossi [2,3].  Delivery strategies can be generally 
categorized into two approaches, including chemical modification and nanoparticle 
formulation.  Over the past year, significant advance in siRNA delivery has been made.  The 
key discoveries and technologies are highlighted and compared in this chapter.  The 
perspectives and future directions are also discussed. 
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1.1 DELIVERY BARRIERS FOR SIRNA 
There are at least five major barriers that prevent efficient delivery of siRNA into target cells 
[4], including (a) siRNA degradation by the nuclease in the blood and extracellular fluids, (b) 
non-specific elimination by the reticuloendothelial system (RES) in the liver and spleen, (c) 
extravasation of siRNA into the target tissue, (d) cell membrane penetration and (e) escape of 
the siRNA from the endosome and/or the carrier into the cytoplasm.  To achieve a significant 
gene silencing effect, a variety of different strategies have been developed to overcome the 
barriers. 
1.2 SIGNIFICANT PROGRESS OVER THE PAST YEAR 
1.2.1 Chemical modification approach 
Chemical modification of siRNA involves the modification on the nucleic acid backbone to 
increase the nuclease resistance and/or the conjugation of a lipophilic moiety at the end of 
sequence to improve the membrane penetration [2,4].  Backbone chemistry includes 2’-
fluoro, 2’-O-methyl and phosphothioate.  Cholesterol is the most commonly used moiety for 
increasing the cellular bioavailability. 
1.2.1.1 Mechanisms and optimization of in vivo delivery of lipophilic siRNA 
Cholesterol-conjugated siRNA has been shown to silence gene in vivo, especially in the liver 
and the intestine.  Wolfrum et al. synthesized a variety of lipid-conjugated siRNA to study 
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the mechanism of tissue targeting [5].  They found that selective tissue uptake of the siRNA 
conjugates was due to the binding with serum lipoproteins.  Conjugates that had high affinity 
for serum albumin over lipoproteins showed little liver uptake, leading to an insignificant 
RNAi effect.  On the other hand, lipophilic siRNA that showed high association with 
lipoproteins had improved liver uptake and gene silencing activity.  They demonstrated that 
high-density lipoprotein (HDL) enhanced the uptake of conjugated siRNA in the liver, gut, 
kidney and steroidogenic tissues via the scavenger receptor BI (SR-BI).  Some lipophilic 
siRNA also bound with low-density lipoprotein (LDL) and were delivered to the liver 
through the LDL receptor.  Additionally, the transmembrane protein Sid1 was required for 
the cellular uptake of the conjugated siRNA complexed with lipoproteins.  It is noted that 
cholesterol conjugated siRNA against apolipoprotein B (apoB) decreased the serum level of 
LDL, which happened to be its major carrier.  It is expected that the gene silencing effect of 
the subsequent administrations should be compromised.  It may be argued that the serum 
level of LDL can serve as a regulator for the degree of gene silencing in order to maintain a 
desirable pharmacological effect.  Nevertheless, when the siRNA is designed for other 
targets, the activity will be highly dependent on the LDL level in the individual, leading to a 
possible high degree of variability. 
 Recently, DiFiglia and colleagues utilized the facts that the cholesterol conjugated 
siRNA is carried by the LDL and LDL receptors have been detected in the brain to deliver 
siRNA into the mouse brain [6].  The cholesterol conjugated siRNA targeting human 
huntingtin (Htt) mRNA was introduced intrastriatally into the striata of mice that received 
adeno associate virus (AAV) containing expanded or wild-type Htt cDNA earlier.  Both 
wild-type and mutant human Htt were down-regulated in the mouse striatum by a single 
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injection of the cholesterol-siRNA.  The treatment significantly prolonged the survival of 
striatal neurons, reduced neuropil aggregates, decreased inclusion size, and improved the 
movement of the treated mice. 
1.2.1.2 Dynamic PolyConjugates for targeted delivery of siRNA 
Rozema et al. attached the backbone modified siRNA with the so-called dynamic 
PolyConjugates composed of a backbone polymer (amphipathic poly(vinyl ether)), a pH 
sensitive linker (CDM, carboxy dimethylmaleic anhydride), polyethylene glycol (PEG) and a 
targeting ligand (NAG, N-acetylgalactosamine) [7].  The amine group in the backbone 
polymer was masked with PEG and the ligand via the pH sensitive linker.  PEGylated 
approach was utilized to improve the pharmacokinetics of the conjugate and the NAG ligand 
was employed to enhance the hepatocyte delivery by targeting the asialoglycoprotein 
receptor.  Once the conjugates were internalized by the receptor-mediated endocytosis and 
trapped inside the acidic endosome, the acid labile linker was cleaved and the amine group in 
the polymer was unmasked, which destabilized the endosomal membrane and mediated 
endosome rupture.  Using this delivery technology, they successfully demonstrated effective 
knockdown of two endogenous genes in the mouse liver: apoB and peroxisome proliferator-
activated receptor alpha (ppara).  Downregulation of apoB led to a significant reduction in 
serum cholesterol with little toxicity. 
1.2.2 Nanoparticle approach  
Different from the chemical modification method, the nanoparticle formulation strategy 
usually involves with encapsulating native siRNA into the particles, which prevents the 
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direct contact of nucleases with the siRNA.  In addition, with the size around 100 nm, the 
renal clearance for the nanoparticles is minimal, resulting in prolonged blood circulation time 
and selective tissue accumulation [e.g. highly vasculatured tumor via the enhance 
permeability and retention (EPR) effect].  Nanoparticles can be generally categorized into 
two groups: lipid based and polymer based.  Usually, four major components are 
incorporated in the formulation to overcome delivery barriers, including (a) a cationic carrier 
to condense siRNA into nanoparticles, (b) PEG to introduce steric hindrance for the 
nanoparticles to improve the circulation time and pharmacokinetics, (c) a targeting ligand to 
enhance the intracellular delivery and (d) an endosomolytic component, such as poly-
imidazole or poly-histidine, to increase the bioavailability of the internalized siRNA.  The 
advance of the nanoparticle formulation in these four aspects is discussed in the following  
sections and summarized in table 1.1. 
 
Table 1.1 Summary of siRNA delivery technologies using nanoparticle approach 
Strategies Advances 
Functional components Examples 
Improved 
nanoparticle 
complexation 
1. Incorporation of a high MW nucleic 
acid 
2. Introduce sticky overhangs to the 
siRNA 
1. Calf thymus DNA [8] 
2. A5-8/T5-8 overhangs [9] 
Improved 
pharmacokinetics 
Surface coating with a hydrophilic 
polymer 
PEGylation [8,10-12] 
Enhanced 
intracellular 
delivery 
Surface conjugation of a targeting 
ligand 
Anisamide [8], transferrin 
[10], transferrin antibody 
[12] 
Increased 
endosomal release 
Incorporation of an endosomolytic 
component 
1. poly-imidazole [10] 
2. poly-histidine [12] 
1.2.2.1 Complexation of siRNA with cationic carriers 
The most commonly used method for forming nanoparticles with siRNA is through a self-
assembling process mediated by charge-charge interaction, in which the cationic vector binds 
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with the anionic nucleic acid.  The particle complexation is usually performed in a diluted 
concentration to avoid aggregation.  Several groups found that cationic carriers, especially 
for polymers, formed looser complexes with siRNA than with plasmid DNA, resulted in 
unstable particle formation and reduced delivery efficiency [8,9].  This is probably due to the 
fact that the molecular weight of the siRNA is too low for an efficient polymer interaction.  
Li et al. mixed a carrier DNA, calf thymus DNA (average size 50 kbp), with the siRNA in 
their system to enhance the particle compaction [8].   The siRNA mixing with the calf 
thymus DNA was tightly complexed with protamine into a solid core, which was further 
coated with cationic lipid bilayers [so-called LPD (liposome-polycation-DNA) 
nanoparticles].  This improved formulation showed 10-30% decreased size and 20-80% 
increased delivery efficiency comparing with the formulation without the carrier DNA.  
Although the calf thymus DNA with limited immuno-stimulating CpG motifs did not 
enhance the immunotoxicity of the formulation; the foreign DNA containing nanoparticles 
may not be suitable for human use.  Bolcato-Bellemin and colleagues added short 
complementary A5-8/T5-8 overhangs to make the siRNA bind to each other and form a large 
“gene-like” structure [9].  They found that the siRNA with the sticky overhangs had 
increased complex stability with polyethyleneimine (PEI), improved RNase protection and 
enhanced gene silencing up to 10-fold.  After released in the cytoplasm, the sticky siRNA did 
not induce interferon response, suggesting the approach may be a good alternative. 
1.2.2.2 Modification of nanoparticles with PEG 
PEGylation technology has been widely used to improve the stability, blood circulation time 
and pharmacokinetics of biopharmaceutical agents, such as nucleic acids and proteins.  
Surface coating of PEG on the liposomes has been shown to prevent particle aggregation and 
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reduce the opsonization with the serum proteins, leading to decreased RES uptake and 
prolonged circulation time.  Thus, surface PEGylation has been commonly employed in the 
nanoparticle field.  Since PEG may interfere with the charge-charge interaction during the 
particle formation due to its steric hindrance, the PEGylation process is often performed after 
the particles are formed, especially for the lipid-based nanoparticles [8,12].  Linear cationic 
polymer, on the other hand, is usually PEGylated before complexed with siRNA [11], and 
therefore, has less problem of forming aggregates.  For PEGylated cationic polymer, the 
positively charged functional groups are still available for siRNA if the ratio of PEG/charged 
groups is designed properly.  Whereas the surface charge of the lipid based vesicles is greatly 
shielded by PEG and no longer accessible for siRNA. 
 Although significant efforts have been placed on finding other type of materials to 
replace PEG, little success has been reported. 
1.2.2.3 Conjugation of a targeting ligand 
For membrane impermeable drugs, such as siRNA, extracellular release is not a good design 
for the delivery.  Once the nanoparticles extravasate in the local tissue (e.g., solid tumor), an 
intracellular uptake mechanism is needed to increase the bioavailability of siRNA.  
Conjugating a targeting ligand on the surface of the nanoparticle is the most commonly used 
strategy.  A variety of targeting ligands have been used, including small molecule ligand [8], 
peptide [13], protein [10] and antibody [12].  After the ligand binds with the receptor 
overexpressed on the target cell surface, the receptor-mediated endocytosis is triggered for 
the internalization of the siRNA containing nanoparticles.  However, some problems have 
been reported regarding the use of the targeting strategy.  First, the antibody conjugated 
liposomes (immunoliposomes) had reduced circulation time after repeated injections, 
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suggesting that an immune response against the immunoliposomes was produced [14].  
Second, the high-affinity binding of the ligand and receptor often results in tight association 
of the targeted nanoparticles with the target cells near the vasculature, leading to reduced 
tissue penetration [15].  Therefore, the new criteria for selecting targeting ligands have been 
changed: (a) an endogenous ligand that does not induce immune response, (b) a ligand that 
binds with the surface receptors overexpressed in the target cell and triggers rapid 
endocytosis, (c) a ligand that binds with the receptor with a relatively low affinity allowing 
improved tissue penetration [15]. 
 It is noted that the modification of a targeting ligand on nanoparticles does not 
increase the target tissue accumulation but improve the intracellular delivery.  Li et al. 
demonstrated that the pharmacokinetic parameters (clearance, area under the curve and mean 
residence time) remained the same for non-targeted and targeted nanoparticles, while the 
targeted nanoparticles showed improved intracellular delivery and RNAi effect [8].  Bartlett 
also published similar results showing that the targeted nanoparticles had similar 
pharmacokinetics as the non-targeted nanoparticles, but had enhanced gene silencing effect 
[10]. 
1.2.2.4 Incorporation of an endosomolytic component 
Once internalized into the target cell, the nanoparticles are trapped inside the 
endosome/lysosome and finally degraded in the acidic and enzyme-rich environment.  The 
siRNA needs to be released to the cytoplasm in order to have its pharmacological activity.  
To further improve the RNAi activity, an endosomolytic component is incorporated in the 
nanoparticle formulation.  Usually, the endosomolytic agent contains multiple neutral amine 
groups with a pKa around 6.5, such as crowded tertiary amines [16,17], histidine [10] and 
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imidazole [12].  At physiological pH, the amine groups stay neutral; while in the endosome 
(pH 5-6), the amine groups are protonated.  This results in reduced free proton concentration 
and increased pH in the endosome.  Due to the continuous influx of proton and its counter 
anion, chloride, into the endosome to maintain the low pH, the osmotic pressure in the 
endosome rises rapidly.  Eventually, the endosome ruptures and nanoparticle/siRNA is 
released.  The process is called the proton sponge effect [16] and has been experimentally 
verified [17]. The release of siRNA from the nanoparticle is probably the result of protein 
competition for polymer binding, although it has not been experimentally verified. The 
strategy has been shown to significantly increase the RNAi effect of the formulation [12]. 
For a cationic lipid based delivery system, formation of charge complex between the cationic 
lipid and the anionic endosomal lipid may lead to local dehydration and destabilization of the 
endosomal membrane [18], resulting in the release of the siRNA/lipid complex into the 
cytoplasm. 
1.2.3 Other approaches 
Kumar et al. developed a chimeric peptide consisting of a 29-amino-acid peptide derived 
from rabies virus glycoprotein (RVG) tethered to a 9-arginine (9R) peptide [13].  The RVG 
peptide was shown to specifically bind to the acetylcholine receptor expressed in neuronal 
cells and the 9R could complex with siRNA as a delivery moiety.  They demonstrated that 
siRNA could be transvascularly delivered into the neuronal cells with the chimeric peptide 
by i.v. injection.  Specific gene silencing and antiviral activity was observed with little 
toxicity.  Medarova et al. chemically conjugated a polyarginine peptide, a siRNA and a near 
infrared fluorescent dye (Cy5.5) onto a dextran coated magnetic nanoparticle to image the 
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tumor accumulation and the RNAi effect of the formulation by magnetic resonance imaging 
(MRI) and optical imaging [19]. 
1.2.4 Management of immunotoxicity of siRNA 
siRNA can be potent triggers for the immune response, particularly when associated with 
delivery vesicles that facilitate intracellular uptake. Judge et al. identified 5’-UGUGU-3’ 
within siRNA as one immunostimulatory motif and showed that the sequence recognition 
mechanism is stringent enough that minimal base substitution can have profound effects to 
reduce the immune response [20]. They showed that immune stimulation by synthetic siRNA 
can be completely diminished by selective incorporation of 2’-O-methyl (2’OMe) uridine or 
guanosine nucleosides into one strand of the siRNA duplex. The modified siRNA had full 
gene silencing activity and was tested in mice without generating cytokine induction, toxicity 
or off-target effects [21]. Recently, Robbins and colleagues showed that 2’-O-methyl-
modified siRNA acted as a TLR7 antagonist that abolished the inflammatory toxicity of the 
immunostimulatory siRNA and a small-molecule TLR7 agonist, loxoribine [22]. 
1.3 PERSPECTIVES FOR SIRNA DELIVERY 
siRNA based gene therapy has become one of the major focuses in the gene therapy field.  
First, the action site of siRNA is located in the cytosol, which avoids the requirement of 
nuclear delivery; a significant barrier for plasmid DNA based therapy.  Second, siRNA is the 
most efficient antisense agent among oligonucleotides with a relatively low off-target effect.  
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Third, like all other oligonucleotides, siRNA can be chemically synthesized in high quantity 
and purity to meet the standards of a pharmaceutical grade drug.  The significant progress 
over the past year highlighted above promises the future of siRNA as a new class of 
promising pharmaceutical.  However, there are still several challenges ahead.  In this section, 
different strategies for siRNA delivery are compared and the future perspectives are 
discussed. 
1.3.1 Viral vs non-viral vector; expression vector vs synthetic siRNA 
Unlike non-viral approach, viral delivery employs an expression vector to be transcribed into 
shRNA (short hairpin RNA) after delivered into the nucleus.  shRNA then translocates into 
the cytoplasm and is processed by the Dicer into siRNA.  Once the expression vector is 
integrated into the chromosome of the infected cell, siRNA is continuously expressed, which 
promises its long-term therapeutic effect.  However, viral vector suffers from poor tissue 
targeting and high immunogenecity [23], resulting in little success compared to non-viral 
vectors.  The difficulty in nuclear delivery bars the success of using non-viral vector to 
deliver a siRNA expression vector.  In addition, the short half-life of siRNA requires multiple 
injections of the non-viral formulation to achieve a significant therapeutic effect 
[8,12,13,19,24].  Although chemical modification may improve the biochemical stability of 
siRNA in the cytosol, more effort should be placed to solve this problem, such as the design 
of a sustained release carrier. 
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1.3.2 Chemical modification vs nanoparticle formulation approach 
Wolfrum et al. showed that the lipophilic siRNA bound with different endogenous carriers 
for tissue targeting [5].  However, the application of the chemically conjugated siRNA is still 
limited for liver diseases.  Different types of conjugation and their pharmacokinetics need to 
be studied to broaden the scope of the approach.  Nanoparticle vector is mainly focused on 
the delivery to the highly vascularized inflammatory tissue or tumor by utilizing the EPR 
effect of the nanoparticle.  Combination of these two approaches may expand the application 
and prolong the RNAi effect. Since the lipophilic siRNA binds to a natural nanoparticle 
carrier, i.e., lipoprotein, both approaches have the same limitation of being effective only 
with tissues equipped with a leaky vasculature. Delivery of siRNA to tissues with a tight 
vasculature, such as brain and muscle, will continue to be a challenge. In this regard, tissue-
tropic viral vectors, such as AAV, may be a good alternative. 
1.3.3 Self-assembled nanoparticles vs chemically conjugated nanoparticles 
Self-assembled nanoparticles are formed by mixing siRNA with a vector and the siRNA is 
encapsulated inside the nanoparticles by non-covalent forces.  Preparation of chemically 
conjugated nanoparticles usually involves with a series of chemistry, and the siRNA is 
attached to the surface of the vector by covalent bonds.  The magnetic nanoparticle used by 
Medarova et al. [19] is a good example of the latter nanoparticle carrier. These two types of 
nanoparticles can be compared in two aspects, stability and drug/carrier ratio.  Fist, siRNA is 
encapsulated inside the self-assembled nanoparticles, which prevents direct contact of the 
siRNA with nucleases and increases the stability.  However, conjugation of siRNA on the 
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surface of the nanoparticles does not offer equal protection.  During the chemical conjugation 
and purification process, loss of siRNA or its stability likely occurs.  Additionally, shelf-life 
and scale-up production of the nanoparticles needs to be studied.  On the other hand, self-
assembled nanoparticles is usually prepared by mixing different components before use 
[8,11,12], which avoids the storage of the nanoparticles.  Polymer and lipid vectors can be 
easily scaled up.  Second, self-assembled nanoparticles provide a much higher drug/carrier 
ratio compared to the chemically conjugated nanoparticles.  For examples, Bartlett and Davis 
demonstrated that each of their self-assembled nanoparticles contained ~2,000 siRNA 
molecules [25], while Medarova’s chemical conjugation method could only attach three 
siRNA molecules to a single nanoparticle [19].  Here, we predict that self-assembled 
nanoparticles will continue to dominate for siRNA delivery. 
1.3.4 Multiple siRNA sequences delivery 
Using multiple siRNA sequences to attack different regions of the same target mRNA or to 
simultaneously silence different genes is a common practice in RNAi research.  Recently, 
Castanotto et al. found that siRNA can potentially compete or hinder the transport and 
incorporation of other siRNA sequences into the RNA-induced silencing complex (RISC) 
when used in a combinatorial approach [26].  TAR RNA binding protein is one of the sensors 
for selecting and incorporating the sequences of siRNA.  Therefore, combinatorial siRNA 
strategy can be problematic.  Improved pharmacological effects may only be achieved when 
different targets are simultaneously silenced.  Theoretically, siRNA against the gene with a 
long half-life should be given first followed by the siRNA targeting the gene with a shorter 
half-life.  siRNA targeting an abundant mRNA may have to be administered multiple times 
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for sufficient gene silencing before the treatment of other siRNA.  Therefore, intensive 
pharmacokinetic and pharmacodynamic studies should be performed to fine tune the dosing 
regimen (dose, interval, frequency, order) for the combinatorial approach in order to achieve 
a synergistic effect. 
1.3.5 Targeting diseased cells vs the surrounding vascular endothelial cells 
There has been an increased interest of targeting the surrounding vascular endothelial cells in 
a diseased tissue (so-called anti-angiogenesis approach), especially for tumor and 
inflammatory diseases.  There are several advantages for the anti-angiogenesis approach.  
First, endothelial cells directly facing the blood are more accessible for treatment compared 
to the diseased cells.  Taking tumor as an example, the intratumoral pressure is significantly 
higher compared to the peripheral, often resulting in low tissue penetration of the siRNA 
formulation.  Second, multiple mutated signal transduction pathways are often found in the 
tumor cells, which makes it difficult to treat the disease by using a limited number of siRNA 
sequences.  On the other hand, vascular biology is usually more constant and therefore, more 
readily for intervention.  Third, specific antibody can be produced to transvascularly deliver 
nanoparticles into the target tissue.  Oh and colleagues showed that the aminopeptidase P 
antibody targeted nanoparticles to the caveolae of mouse lung endothelium [27].  The 
caveolae then operated as a pump, transporting the antibody conjugated nanoparticles from 
the blood across the endothelium into the lung tissue.  Approximately 80% injected dose/g 
tissue was achieved within 30 min with minimal uptake in other tissues.   Although most of 
the published methods used diseased cell targeting approach, it is anticipated that an 
increased number of research utilizing vascular targeting method will be reported. 
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1.3.6 Other critical issues 
Other than the topics discussed above, there are at least five critical issues that need to be 
considered for developing a siRNA formulation. 
1.3.6.1 siRNA release from the nanoparticles 
Significant effort has been placed on improving the complexation of siRNA into 
nanoparticles, while the mechanism of siRNA release in the cytoplasm needs further study.  
Only the released siRNA is bioavailable.  If the siRNA can be programmed for sustained 
release, the RNAi effect can be greatly prolonged. 
1.3.6.2 Pharmacokinetics/biodistribution 
Pharmacokinetic study allowing describing and predicting the behavior, efficacy and toxicity 
of siRNA formulation will eventually become a prerequisite.  Several methods have been 
used for the study of pharmacokinetics of siRNA, including fluorescence labeling [8], 
radioisotope labeling [10], RNase protection assay [12] and LC-MS method.  From the 
pharmaceutical point of view, only the LC-MS method is robust enough to perform the 
validated analysis.  Unfortunately, LC-MS method is still limited by its low sensitivity.  
Therefore, a sensitive LC-MS method for siRNA is urgently needed. 
1.3.6.3 Stability 
Stability is a key issue for pharmaceutical products.  Stability test has to be performed in the 
early stage of formulation development, which will eventually affect its clinical use.  
Stability can be monitored by measuring the particle size, zeta potential, encapsulation 
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efficiency and gene silencing activity.  For an unstable formulation, lyophilization is a 
commonly used method for long term preservation [28]. 
1.3.6.4 Toxicity 
Preliminary toxicity of the formulation can be evaluated by blood chemistry, liver enzyme 
analysis, body-weight monitor and proinflammatory cytokine analysis in rodents.  However, 
dose escalating study should be done in non-human primates to study the complement 
depletion and antibody production against the nanoparticle formulation [11]. 
1.3.6.5 Dose 
The required dose reflects the delivery efficiency of a formulation.  Low required dose 
usually results in low side effects from the delivery vector and improved therapeutic window.  
Table 1.2 indicates that the self-assembled nanoparticles showed the highest delivery 
efficiency according to the required dose, followed by the chemically conjugated 
nanoparticles and chemically modified siRNA. 
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Table 1.2 Comparison of the siRNA formulations 
Category Formulation Required 
dose 
(mg/kg) 
Times of 
repeated 
injections 
Native 
siRNA 
(N) or 
modified 
siRNA 
(M) 
Target 
tissue 
Re-
ference 
Anisamide-
LPD 
1.2 3 N Tumor [8] 
Transferrin-
cyclodextran 
polycation 
2.5 2-3 N Tumor [24] 
Self-
assembled 
nanoparticles 
Immuno-
lipoplex 
3 3 M Tumor [12] 
Peptide based 
vector 
RVG  
peptide-9R 
2.5 3 N Brain [13] 
Chemically 
conjugated 
nanoparticles 
Magnetic 
nanoparticles 
~6 4 N Tumor [19] 
Dynamic 
Poly-
conjugates 
~2.5 1 M Liver [7] Chemically 
modified 
nanoparticles 
Cholesterol-
siRNA 
50 1 M Liver [5] 
 
2.0  DEVELOPMENT AND CHARACTERIZATION OF THE LPD (LIPOSOME-
POLYCATION-DNA) NANOPARTICLE FORMULATION FOR SIRNA 
LPD (liposome-polycation-DNA) nanoparticles prepared by mixing cationic liposomes, a 
polycationic peptide, and nucleic acids showed a virus like structure at a certain composition.  
Nucleic acids were condensed by the peptide and formed a compact core, which was coated 
by two lipid bilayers.  The inner bilayer was hypothetically supported by charge-charge 
interaction of the cationic lipids and the negatively charged complex core.  In this study, we 
showed that LPD had improved stability compared to the cationic liposomes after the post-
insertion of 10 mol% DSPE-PEG (distearoyl phosphatidyl ethanolamine-polyethylene glycol 
2000).  The light scattering data showed that the small size particle population significantly 
increased after PEGylation in the cationic liposomes compared to the LPD nanoparticles.  
LPD prepared by a multivalent cationic lipid, DSGLA (distearoyl guanidine lysine amide), 
had enhanced stability compared to that consisting of DOTAP (dioleoyl triammonium 
propane), a monovalent cationic lipid.  The data suggest that stability of the LPD could be 
further improved by an enhanced charge-charge interaction.  Distinct nanoparticle structure 
of the LPD after PEGylation was still found in the negative-stained electronic microscopy, 
while the cationic liposomes were transformed into tubular micelles under the same 
condition.  Size exclusion chromatography data showed that approximately 60% of the total 
cationic lipids (62.8 ± 4.6%), which was located in the outer bilayer of the LPD according to 
the calculation, was stripped off during the PEGylation; and about 20% of the input DSPE-
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PEG (20.6 ± 3.4%) was incorporated onto the inner bilayer of LPD with about 10.6 mol% of 
DSPE-PEG presented on the particle surface.  This led to a complete charge shielding (zeta 
potential = -5.6 ± 4.5 mV) and abolishment of liver sinusoidal uptake in the isolated liver 
perfusion model. Our results demonstrated the importance of the supported bilayer in 
improving the stability of a nanoparticle formulation. 
2.1  INTRODUCTION 
 
Prolongation of the circulation half-life by surface incorporation of PEG in liposomes was 
demonstrated by our group in 1990 [29].  Surface modification by PEG was shown to reduce 
non-specific uptake of liposomes by the reticuloendothelial system (RES) in the liver and the 
spleen and thus improved its pharmacokinetic property.  PEGylation approach has been used 
in a variety of nanoparticle systems to enhance the drug delivery.  
LPD (liposome-polycation-DNA) nanoparticle was developed earlier in our lab [30] 
and has been used for the delivery of peptide [31] and nucleic acid, including plasmid DNA 
[30], oligonucleotide  and siRNA [8,32-34].  LPD was prepared by mixing cationic 
liposomes, a polycationic peptide and nucleic acids at a fixed ratio.  The self-assembled 
nanoparticles are around 100 nm in diameter.  The detail structure of the LPD was 
demonstrated by the cryo-TEM (transmission electron microscopy) (figure 1A) [35], 
showing that the nucleic acid was complexed by protamine to form a compact core, which 
was coated with two cationic lipid bilayers (figure 1B).  According to the calculation on the 
cryo-TEM picture (figure 1A), the ratio of the surface area of the inner bilayer and outer 
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bilayer was 1:1.8, indicating that approximately 36.4% of the total lipids was located in the 
inner bilayer and 63.6% was in the outer bilayer.  The formation mechanism of the LPD has 
been proposed (figure 1C) [35].  First, the cationic peptide interacted with the nucleic acid 
and formed a negatively charged complex, which then interacted with the cationic liposomes 
via a charge-charge interaction.  Second, upon the strong charge-charge interaction, the 
liposomes collapsed onto the peptide-nucleic acid complex core.  Third, two separate lipid 
bilayer membranes appear on the surface of the LPD nanoparticle as the result of bilayer 
fusion and re-organization. In this model, the inner bilayer is directly in contact with the core 
and is supported and stabilized by the charge-charge interaction of the cationic lipids and the 
negatively charged complex core.  We hypothesized that a supported bilayer tolerates a high 
level of DSPE-PEG, which is a surfactant, better than a regular bilayer.  This unique feature 
of LPD may provide us an opportunity to modify the formulation with a high amount of 
DSPE-PEG to achieve an enhanced surface shielding and thus improve the pharmacokinetic 
property of the nanoparticle formulation. 
In this study, we evaluated the tolerance of liposomes and LPD to DSPE-PEG micelle 
by using light scattering and TEM.  We also titrated the input amount of DSPE-PEG micelle 
for the post-insertion and monitor the stability of the nanoparticles.  Size exclusion 
chromatography was performed to purify and characterize the PEGylated LPD.  Finally, the 
surface shielding effect of the PEGylated LPD was assessed by measuring the zeta potential 
and the non-specific uptake by the liver sinusoidal cells in the isolated liver perfusion model. 
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Figure 2.1 Illustration of the formation of LPD. 
Cryo-TEM photograph (A), the illustration of the double lipid bilayer structure (B) and proposed mechanism for 
the formation of the LPD nanoparticles (C).  Figure 1A was reproduced from Tan et al. with the authors’ 
permission [35]. 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
DOTAP (dioleoyl triammonium propane) (figure 2.2A), NBD-DOTAP (nitrobenzosadiazol-
DOTAP), NBD-PE (NBD-phosphatidyl ethanolamine), cholesterol, DSPE-PEG2000 
(distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000), and DSPE-PEG2000-
carboxyfluorescein (DSPE-PEG-CF) were purchased from Avanti Polar Lipids, Inc. 
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(Alabaster, AL).  Protamine sulfate (fraction X from salmon sperm), calf thymus DNA (for 
hybridization, phenol-chloroform extracted and ethanol precipitated), and Sepharose CL 2B 
were from Sigma-Aldrich (St. Louis, MO).  DSGLA (distearoyl guanidine lysine amide) was 
synthesized in our lab and the structure is shown in figure 2.2A. 
Anti-luciferase siRNA (GL3) (target sequence 5'- CTT ACG CTG AGT ACT TCG A 
-3') was purchased from Dharmacon (Lafayette, CO) in deprotected, desalted, annealed form.  
Fluorescein (FAM) labeled siRNA (3’ end of the sense strand) was used to evaluate the 
incorporation efficiency of the LPD for siRNA.  Cy3 labeled siRNA was used for the isolated 
liver perfusion study. 
  
2.2.2 Experimental animals 
Female C57BL/6 mice of age 6-8 week (16-18 g) were purchased from Charles River 
Laboratories (Wilmington, MA).  All work performed with animals was in accordance with 
and approved by the IACUC committee at the University of North Carolina at Chapel Hill 
(UNC). 
2.2.3 Preparation of siRNA containing LPD nanoparticles 
Two different methods were developed for the preparation of unmodified LPD nanoparticles.  
The two methods used the same ratio of cationic liposomes, protamine and nucleic acid, and 
the characteristics (particle size, zeta potential and encapsulation efficiency) of the 
nanoparticles prepared by the two methods were similar to each other. 
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Method 1: Small unilamellar liposomes consisting of DOTAP and cholesterol (1:1 
molar ratio) were prepared by thin film hydration followed by membrane extrusion through a 
50 nm polycarbonate membrane by 10-15 times. The total lipid concentration of the liposome 
was fixed at 10 mM and the liposome size was 90-100 nm. LPD was composed of 
DOTAP/cholesterol liposome, protamine, and the mixture of siRNA and calf thymus DNA 
(1:1 weight ratio). To prepare LPD, 15 μl of protamine (2 mg/ml), of 138 μl nuclease free 
water, and 24 μl of a mixture of siRNA and calf thymus DNA (2 mg/ml) were quickly mixed 
in a 1.5 ml tube. The complex was allowed to stand at room temperature for 10 min before 
the addition of 123 μl of DOTAP/cholesterol liposome (total lipid concentration = 10 mM). 
LPD nanoparticles were kept at room temperature for another 10 min before further 
application. 
Method 2: LPD was obtained by quickly mixing suspension A (8.3 mM liposomes 
(DOTAP: cholesterol = 1: 1, molar ratio) and 0.2 mg/ml protamine in 150 μl nuclease free 
water) with solution B (0.16 mg/ml siRNA and 0.16 mg/ml calf thymus DNA in 150 μl 
nuclease free water) followed by incubation at room temperature for 10 min.   
PEGylated LPD was prepared by incubating the LPD suspension (300 μl) with 37.8 
μl micelle solution of DSPE-PEG (10 mg/ml) at 50°C for 10 min.  PEGylated LPD was 
allowed to stand at room temperature for 10 min.   
The charge ratio of the formulation was about 1:5 (-:+).  The particle size was 
measured using the submicron particle sizer (NICOMP particle sizing systems, AutodilutePAT 
Model 370, Santa Babra, CA) in the NICOMP mode.  The zeta potential of various LPD 
formulations diluted in 1 mM KCl was determined by using a Zeta Plus zeta potential 
analyzer (Brookhaven Instruments Corporation, Holtsville, NY).  PEGylated LPD was 
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freshly prepared and used within 20 min for the following experiments.  For size exclusion 
chromatography, either 10 mol% NBD-DOTAP labeled liposomes, 10 mol% DSPE-PEG-CF 
labeled DSPE-PEG or FAM-siRNA was used for the preparation of the PEGylated LPD. 
2.2.4 Negative stain electron microscopy 
Transmission electron microscope (TEM) images were acquired using a Phillips CM12 (FEI, 
Hillsboro, OR). Briefly, freshly prepared formulations (5 μl) samples were dropped onto 300 
mesh carbon-coated copper grids (Ted Pella, Inc., Redding, CA) and allowed a short 
incubation (5 min) at room temperature. Grids were then stained with 1% uranyl acetate (40 
μl) and wicked dry. All images were acquired at an accelerating voltage of 100 kV. Gatan 
Digital Micrograph software was used to analyze the images. 
2.2.5 Size exclusion chromatography 
Ten μl of the samples was loaded onto a PBS pre-equilibrated Sepharose CL 2B column (1 × 
10 cm).  Elute fractions (200-300 μl) were collected, diluted 1:1 in ethanol, and analyzed for 
fluorescence intensity by a plate reader (λex: 485 nm, λem: 535 nm) (PLATE CHAMELEON 
Multilabel Detection Platform, Bioscan Inc., Washington, DC). 
2.2.6 Cellular Uptake Study  
NCI-H1299 cells (1X105 cells/well) were seeded in 12-well plates (Corning Inc., Corning, 
NY) 20 h before experiments. Cells were treated with different formulations at a 
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concentration of 100 nM siRNA in serum containing medium at 37 oC for 4 h. Cells were 
washed twice with PBS, followed by incubation with lysis buffer (0.3% triton X-100 in PBS) 
at room temperature for 1 h. Fluorescence intensity of cell lysate was determined by a Perkin 
Elmer LS 50B Luminescence spectromer (Norwalk, CT) (λex: 494 nm, λem: 519 nm). For 
free ligand competition study, cells were co-incubated with 50 µM haloperidol with 
formulations.  Alternatively, cells were fixed with methanol at room temperature for 1 min, 
mounted onto a glass slide, and imaged by a Nikon fluorescence phase contrast optical 
microscope. 
2.2.7 Isolated liver perfusion study 
C57BL/6 mice were sacrificed and the interior vena cava was incised to allow the blood flush 
out when 3 ml of warm PBS was infused into the mouse liver through the portal vein.  cy3-
siRNA containing LPD formulations (300 μl) were incubated with 50 μl mouse serum at 
37°C for 10 min, and then diluted with PBS (final volume = 1 ml).  The complex was infused 
into the isolated liver via the portal vein.  Finally, the liver was perfused with 3 ml warm 
PBS, excised, fixed in 3.6% paraformaldehyde in PBS for overnight, and frozen sectioned (5 
μm in thickness).  Sections were washed with PBS, permeabilized with 0.1% triton X-100 in 
PBS, stained with Alexa Fluor® 488 Phalloidin (Invitrogen, Eugene, OR), mounted with the 
DAPI containing medium (Vectashield®, Vector Laboratories Inc., Burlingame, CA) and 
imaged using a Leica SP2 confocal microscopy. 
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2.2.8 Statistical analysis 
Data are presented as the mean ± SD.  The statistical significance was determined by using 
the analysis of variance (ANOVA, one way) or the two-sided student t-test.  P values of 
<0.05 were considered to be significant. 
 
 
Figure 2.2 Stability of the nanoparticle formulations upon different degree of PEGylation. 
(A) Chemical structures of DOTAP and DSGLA. (B) Size distribution of different PEGylated formulations.  
Data = mean ± SD, n = 4-6 
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2.3 RESULTS AND DISCUSSION 
DSPE-PEG has been used widely in the lipid based nanoparticle formulations, such as 
liposomes, to increase the blood circulation time [36]. It is also known that incorporation of 
too much DSPE-PEG will disrupt the integrity of the lipid membrane due to its detergent like 
properties [37].  This causes the increase of membrane permeability and drug release.  Since 
the unmodified LPD contains two lipid bilayer membranes, incubation with DSPE-PEG may 
strip off the membranes from the nanoparticles and form micelles of smaller particle size.    
Here, we examined the stability of nanoparticle formulations after the addition of different 
amounts of DSPE-PEG by measuring their particle size distribution.    By using dynamic 
light scattering, only one narrow size distribution around 100 nm was revealed for all four 
formulations, i.e., liposomes and LPD composed of either DOTAP or DSGLA, before the 
addition of DSPE-PEG (figure 2.2B).  However, after the addition of DSPE-PEG, a 
population of smaller particles appeared in a dose dependent manner for both DOTAP and 
DSGLA liposomes.  It is noted that pure DSPE-PEG micelle was undetectable at the 
concentrations used in this experiment.  Thus, the smaller size particles must came off from 
the nanoparticles upon the introduction of DSPE-PEG.  The light scattering method can 
quickly determine the stability of the nanoparticles.  The LPD formulations showed 
significantly higher stability compared to the liposomes.  When 10 mol% of DSPE-PEG was 
added, the LPD formulations remained relatively stable, while the liposome formulations 
showed a significant increase in the smaller size population (~5%).  The light scattering data 
(figure 2.2B) is consistent with the observation by TEM (figure 2.3), in which no distinct 
particles were found in the DOTAP liposomes after PEGylation; only tubular mixed micelles 
were present.  On the other hand, nanoparticles around 100 nm in diameter were still found in 
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the PEGylated LPD formulation containing DOTAP (figure 2.3).  It is also noticed that 
DSGLA (contains 3 positive charges)-LPD showed an improved stability compared to 
DOTAP (contains 1 positive charge)-LPD (figure 2.2B), suggesting that LPD was stabilized 
by charge-charge interaction.  Dynamic light scattering is a convenient method to assess the 
relative stability of the particles. For example, smaller size particles were found in the TEM 
photographs of the PEGylated LPD (figure 2.3, arrow heads), while light scattering data 
showed no presence of smaller particles (figure 2.2B).  It is known that particles of larger 
sizes showed significant higher light scattering compared to smaller size particles at the same 
concentration.  Nevertheless, the dynamic light scattering data provided a quantitative 
comparison of the relative stability of different nanoparticle formulations. 
 
Figure 2.3 TEM photographs of liposomes/PEGylated liposomes and LPD/PEGylated LPD.   
Upper panel scale bar = 200 nm, lower panel scale bar = 100 nm.  Arrows indicate the “sprouts” of the particles 
and arrow heads indicate the small particles. 
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As can be seen in figure 2.3, after 10 mol% PEGylation, DOTAP liposomes had 
transformed into tubular micellar structures, indicating the instability of the formulation.  In 
the PEGylated LPD, however, “sprouts” were found in some of the particles (figure 2.3, 
arrows), suggesting that the lipids in the surface of the LPD were being stripped off and 
became smaller particles (figure 2.4, arrow heads). 
To further characterize the LPD nanoparticles, we used 10 mol% NBD-DOTAP 
labeled liposomes, 10 mol% DSPE-PEG-CF labeled DSPE-PEG or FAM-siRNA to prepare 
the PEGylated LPD.  Sepharose CL 2B column was used to separate particles of different 
sizes.  In this study, a neutral liposome formulation (DOPC/Cholesterol/NBD-PE = 49/49/2, 
molar ratio, mean particle size around 100 nm) was used to calibrate the column.  Cationic 
liposomes and unmodified LPD containing excess positive surface charges formed 
aggregates in the elution medium (PBS) and thus, could not be studied by the 
chromatography.  As shown in figure 2.4A, pure DSPE-PEG could be clearly separated from 
the 100 nm-nanoparticles by the size exclusion column.  At least two particle populations 
were observed in the NBD-DOTAP labeled PEGylated LPD (figure 2.4B).  The first major 
peak coincided with that of the 100 nm-nanoparticles, and the second peak lied between the 
peaks of micelles and 100 nm-nanoparticles.  Nevertheless, the PEGylated liposomes (NBD-
DOTAP labeled) showed less significant first peak but a smear of particle size distribution, 
suggesting the lipid membrane was disrupted in this formulation.  The observation is 
consistent with the dynamic light scattering (figure 2.2B) and TEM data (figure 2.3).  
Moreover, the AUC of the first peak of the PEGylated LPD (NBD-DOTAP labeled) was 
about 37.2% (37.2 ± 4.6%, n = 3).  The data suggest that approximately 37.2% of the total 
lipids were associated with the nanoparticles, while the rest of the lipids were stripped off by 
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the DSPE-PEG micelles and formed smaller particles (< 100 nm).  As mentioned earlier, 
approximately 36.4% (36.4 ± 3.2%, n = 5) of the total lipids was located in the inner lipid 
bilayer of the LPD, suggesting that only the inner lipid bilayer stayed with the nanoparticles.  
The inner cationic lipid bilayer was in direct contact with the negatively charged surface of 
the nucleic acid/protamine core and therefore, was more tolerated to PEGylation compared to 
the outer bilayer.    However, further increase of the input DSPE-PEG to 20 mol% caused 
damage of the supported bilayer.  Only 24.2% of the total cationic lipids remained associated 
with the nanoparticles (data not shown), indicating that 35% of the lipids in the supported 
bilayer was removed.  Although the inner bilayer of the LPD was stabilized by charge-charge 
interaction, it could only tolerate a finite amount of DSPE-PEG.  Figure 2.4C shows that 
around 20.6% (20.6 ± 3.4%, n = 3) of the DSPE-PEG (DSPE-PEG-CF labeled) was 
incorporated with the nanoparticles (first peak) after heating, while about 80% of the DSPE-
PEG formed smaller particles with the cationic lipids stripped off from the nanoparticles.  
Figure 2.4D indicates that the nanoparticles eluted with the first peak containing 90% of 
siRNA, 37.2% of the total lipids and 20.2% of the input DSPE-PEG was the major 
contributor for siRNA delivery for the PEGylated LPD formulation. 
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Figure 2.4 Size exclusion chromatography of different samples.   
(A) chromatography of pure DSPE-PEG and liposomes; (B) chromatography of DOTAP in different 
formulations; (C) chromatography of DSPE-PEG in different formulations; (D) chromatography of different 
components in the PEGylated LPD.  DOTAP liposomes was labeled with NBD-DOTAP, DSPE-PEG micelle 
was labeled with DSPE-PEG-CF and siRNA was labeled with FAM-siRNA.  Data are representative 
chromatography from 2-3 batches of formulations.     
 
Ten microliter of the PEGylated LPD contained 0.71 μg siRNA (loading amount for 
column), 36.71 nmole lipids and 3.99 nmole DSPE-PEG.  The nanoparticles eluted in the 
first peak contained 0.64 μg siRNA, 13.66 nmole lipids and 0.81 nmole DSPE-PEG.  
Assuming that DSPE-PEG was inserted only into the outer leaflet of the supported bilayer 
and the lipid content in the outer and inner leaflet of the bilayer were the same, we calculated 
that 10.6 mol% of the outer leaflet was modified with DSPE-PEG.  This led to a complete 
charge shielding, in which the zeta potential of the purified PEGylated LPD was -5.6 ± 4.5 
mV (figure 2.5C). 
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Figure 2.5 Zeta potential of different formulations.   
(A) LPD; (B) LPD + 10 mol% DSPE-PEG; (C) LPD + 10 mol% DSPE-PEG after purified by the size exclusion 
column (first peak). Data = mean ± SD, n = 3 
 
 
To demonstrate that the DSPE-PEG was incorporated onto the LPD, we conjugated 
the anisamide ligand (AA) onto the distal end of the PEG and compared the delivery 
efficiency of the LPD-PEG and LPD-PEG-AA into the sigma receptor expressing cells, NCI-
H1299.  The chemical structures of the DSPE-PEG and DSPE-PEG-AA are shown in figure 
2.6.  LPD-PEG-AA showed enhanced siRNA delivery into the receptor positive cells (4-fold 
increase) and the improved delivery was partially inhibited by excess amount of the free 
ligand (figure 2.7) [32,33].  The delivery efficiency of the LPD-PEG-AA was not enhanced 
in the receptor negative cells, CHO (data not shown).  The data suggested that DSPE-PEG 
and DSPE-PEG-AA were incorporated onto the surface of the LPD.  Once the AA ligand 
was attached to the LPD, the PEGylated LPD showed improved selectivity for sigma 
receptor positive cells. 
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Figure 2.6 Chemical structures of DSPE-PEG (A) and DSPE-PEG-anisamide (B). 
 
 
 
Figure 2.7 Fluorescence intensities of cells (A) and fluorescence photographs of cells (B) treated with 
FAM-siRNA containing formulations.  
H1299 cells were incubated with different formulations at 37oC for 4 h in the presence (white bars) or absence 
(black bars) of 50 µM haloperidol. Cells were washed and lysis. Cells lysates were analyzed for fluorescence 
intensities by a fluorescence spectrometer (λex: 494 nm, λem: 519 nm). Alternatively, cells were imaged with a 
fluorescence microscope.  * indicates the significant difference between two groups (p<0.05). 
 
As shown in figure 2.5, the zeta potential of the LPD, PEGylated LPD and purified 
PEGylated LPD were 43.2, 20.04, and -5.6 mV, respectively.  Approximately 90% siRNA 
was encapsulated in the purified PEGylated LPD, which was a neutral delivery vehicle.  A 
neutral carrier is desirable for in vivo drug delivery because of its improved 
pharmacokinetics and reduced non-specific interaction with cells or serum protein. 
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To further investigate if the PEGylated LPD showed reduced RES uptake in the liver, 
we performed a liver perfusion assay.  As shown in figure 2.8, 10 mol% PEGylated LPD 
showed little sinusoidal uptake in the liver, while 0 or 5 mol% PEGylated LPD had 
significant RES uptake.  The data suggest that sufficiently PEGylated LPD showing reduced 
RES uptake in the liver may exhibit improved pharmacokinetics for delivering siRNA when 
i.v. administered.  
 
Figure 2.8 Liver sinusoidal uptake of cy3-siRNA (red) in different LPD formulations. 
F-actin outlining the cellular morphology was stained with Alexa Fluor® 488 Phalloidin (green) and nuclei 
were stained with DAPI (blue). Magnification = 1,600 x.  Data are representative pictures from 3 mice in each 
group. 
 
 
  Here, we proposed a model to describe the formation of the PEGylated LPD 
nanoparticles (figure 2.9).  After the addition of DSPE-PEG micelles at 50oC, the micelles 
acted like detergents and stripped off the outer lipid bilayer of the LPD.  In the intermediate 
phase, “sprouts” (outer bilayer being stripped off from the LPD) were formed and eventually 
broken down into smaller PEGylated lipid particles.  The inner lipid bilayer was stabilized by 
charge-charge interaction and therefore, remained intact.  Around 20% of the input DSPE-
PEG was inserted into the outer leaflet of the supported bilayer.  Approximately 10.6 mol% 
of the leaflet was modified with DSPE-PEG, which completely shielded the surface charge of 
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the LPD.  At such a high degree of PEGylation, the PEG was shown to present on the surface 
in the brush mode [38], suggesting the surface was fully protected.  On the other hand, the 
cationic liposomes without supported bilayer were not stable upon the challenge of DSPE-
PEG micelle.  The bilayer was stripped off from the liposomes and became smaller particles. 
Depending on the surface density and molecular weight of the PEG grafted to the 
lipid bilayer, three PEG conformations can be identified [39].  Factors controlling the PEG 
conformation include the distance between the PEG chains in the lipid bilayer (D) and the 
Flory dimension, RF, which is defined as aN3/5 (a is the persistence length of the monomer, N 
is the number of monomer units in the PEG) [40]. Three regimes can be defined: (1) when 
D>2 RF (interdigitated mushrooms); (2) when D<2 RF (mushrooms); and (3) when D< RF 
(brushes) [40]. For a 100 nm-liposome grafted with DSPE-PEG2000, PEG chains have been 
found to be arranged in the mushroom mode in the presence of <4 mol% DSPE-PEG; in the 
transition mode when 4-8 mol% modification; and in the brush mode when >8 mol% 
PEGylation [38].  The brush configuration ensures that the entire surface of NP is covered 
[41]. However, over-crowdedness of the PEG on the surface may decrease the mobility of the 
polymer chains and thus decreases the steric hindrance effect [41].  Therefore, we believe 
that surface modification of PEG2000 slightly greater than 8 mol% is desirable for a stealth 
NP.  In our formulation, the nanoparticle was 10.6 mol% modified with PEG2000, which falls 
in the optimal condition. 
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Figure 2.9 Proposed mechanism for the formation of PEGylated LPD. 
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In the following content, the LPD-PEG is referred to as the non-targeted nanoparticles 
(NP) and LPD-PEG-AA is referred to as the targeted nanoparticles. 
3.0  TUMOR-TARGETED DELIVERY OF SIRNA BY SELF-ASSEMBLED 
NANOPARTICLES 
We have developed a self-assembled nanoparticle (NP) that efficiently delivers small 
interfering RNA (siRNA) to the tumor by intravenous (i.v.) administration. The NP was 
obtained by mixing carrier DNA, siRNA, protamine, and lipids, followed by post-
modification with polyethylene glycol and a ligand, anisamide. Four hours after i.v. injection 
of the formulation into a xenograft model, 70-80% of injected siRNA/g accumulated in the 
tumor, ~10% was detected in the liver and ~20% recovered in the lung. Confocal microscopy 
showed that fluorescent labeled siRNA was efficiently delivered into the cytoplasm of the 
sigma receptor expressing NCI-H460 xenograft tumor by the targeted NPs, whereas free 
siRNA and non-targeted NPs showed little uptake. Three daily injections (1.2 mg/kg) of 
siRNA formulated in the targeted NPs silenced the epidermal growth factor receptor (EGFR) 
in the tumor and induced ~15% tumor cell apoptosis. Forty percent tumor growth inhibition 
was achieved by treatment with targeted NPs, while complete inhibition lasted for 1 week 
when combined with cisplatin. The serum level of liver enzymes and body weight monitoring 
during the treatment indicated a low level of toxicity of the formulation. The carrier itself 
also showed little immunotoxicity. 
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3.1 INTRODUCTION 
Selective oncogene silencing, mediated by small interfering RNA (siRNA), shows promise 
for cancer treatment. However, the obstacles in successfully delivering siRNA hinder the 
therapeutic viability of this treatment [1,4,42]. siRNA are susceptible to nuclease destruction 
and cannot penetrate the cell membrane when used in vivo due to the highly charged nucleic 
acid backbone. Although a variety of delivery systems have been developed for siRNA [2-
4,12,19,24,43-51], the majority of the injected dose (ID) was taken up by the reticular 
endothelial system in the liver and spleen [52]. This typically left only 2-5% of the ID/g 
tissue for the tumor [49,52]; therefore, a more efficient delivery system still needs to be 
found.  
Previously, we have shown that our nanoparticles (NPs) could efficiently deliver 
siRNA to the sigma receptor–expressing lung tumor cells (NCI-H1299), stimulate strong 
RNA interference effects and induce >80% apoptosis in vitro [33]. The targeting ligand, 
anisamide, used in the formulation had a moderate affinity (estimated at Kd ~30 nM) for 
sigma receptors and was shown to increase the intracellular delivery into prostate and lung 
cancer cells [33,34,53]. In this study, we used a more aggressive lung cancer cell line, NCI-
H460, to grow highly vasculatured tumors in vivo. This is a pre-requisite for the enhanced 
permeability and retention (EPR) effect of any NP-based delivery systems [33,34,53]. In the 
Chapter 2, we have shown that the NP contained a supported lipid bilayer to tolerate a high 
degree of PEGylation (10.6 mol%) and thus, the reticuloendothelial uptake in the isolated 
liver perfusion model was completely inhibited. We hypothesized that the highly PEGylated 
NP would have much improved pharmacokinetics in vivo to achieve high tumor 
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accumulation. Additionally, anisamide ligand might further increase the cellular uptake and 
enhance the RNA interference effect.  
The therapeutic target in this study was the epidermal growth factor receptor (EGFR). 
EGFR is over-expressed in a variety of tumors and has been shown to be associated with 
many adverse features of tumor, including increased proliferation, decreased apoptosis, 
enhanced metastasis, and resistance to chemo- and radiation therapy [54,55]. AntiEGFR 
therapy via tyrosine kinase inhibitors and monoclonal antibody has demonstrated great 
benefit for cancer patients [56-59]. Silencing EGFR by RNA interference is an alternative to 
antiEGFR therapy and has already shown some promising results [60-68]. EGFR silencing 
induces cell cycle arrest, apoptosis, tumor cell growth inhibition, and chemosensitization in 
vitro and in vivo [60-68].  
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
NCI-H460 (human lung cancer cells) were obtained from American Type Culture Collection. 
Cells were maintained in Roswell Park Memorial Institute medium 1640 supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100 U/ml penicillin, and 100 μg/ml 
streptomycin (Invitrogen, Carlsbad, CA). NCI-H460 cells were shown to be sigma receptor 
positive by immunostaining and Western blot (data not shown). Primary antibodies against 
EGFR (epidermal growth factor receptor) (rabbit polyclonal), PAR-4 (prostate apoptotic 
response 4) (mouse monoclonal), AIF (apoptosis inducing factor) (rabbit polyclonal) and 
 41
actin/β-actin (mouse monoclonal) were purchased from Santa Cruz Biotechnologies (Santa 
Cruz, CA). 
3.2.2 Experimental animals 
Female athymic nude mice of age 6-8 weeks and female C57BL/6 mice of age 6-7 weeks 
(16-18 g) were purchased from Charles River Laboratories (Wilmington, MA). All work 
performed on animals was in accordance with and permitted by the University of North 
Carolina Institutional Animal Care and Use committee. 
3.2.3 NP preparations 
NPs were prepared by the method described in Chapter 2. Control siRNA that targets the 
sequence 5′-AATTCTCCGAACGTGTCACGT-3′ and EGFR siRNA that targets the 
sequence 5′-AACACAGTGGAGCGAATTCCT-3′ as described previously [67] were 
synthesized in Dharmacon (Lafayette, CO). The control sequence does not match any human 
genome sequence. FAM (fluorescein)-siRNA was also obtained from Dharmacon (Lafayette, 
CO). 
3.2.4 In vitro cellular uptake study  
NCI-H460 cells (1X105 cells/well) were seeded in 12-well plates (Corning Inc., Corning, 
NY) 20 h before experiments. Cells were treated with different formulations at a 
concentration of 320 nM of FAM-siRNA in serum containing medium at 37 oC for 4 h. Cells 
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were washed twice with PBS, fixed with 1% paraformaldehyde in PBS at room temperature 
for 15 min, mounted onto a glass slide, and imaged with a Nikon fluorescence phase contrast 
optical microscope. 
3.2.5 In vitro gene silencing study 
NCI-H460 cells (1X105 cells/well) were seeded in 12-well plates (Corning Inc., Corning, 
NY) 20 h before experiments.  Cells were treated with different formulations at a 
concentration of 120 nM siRNA in serum containing medium at 37 oC for 48 h.  Cells were 
washed, collected and analyzed for EGFR contents by Western Blotting.  Western blot 
method is described in 3.2.10, 
3.2.6 In vitro cytotoxicity study.  
1X105 NCI-H460 cells per well were seeded in 12-well plates (Corning Inc., Corning, NY) 
20 h before experiments.  Cells were treated with different formulations at a concentration of 
320 nM siRNA in serum containing medium at 37 oC for 48 h.  Cells were washed by PBS 
twice, trysinized, collected, incubated with propidium iodide (4 μl of 1 mg/ml stock for 1 ml 
sample), and analyzed by a BD FACScanto digital flow cytometer (San Diego, CA). 
3.2.7 Immunocytochemistry 
1X105 NCI-H460 cells per well were seeded in 12-well plates (Corning Inc., Corning, NY) 
20 h before experiments.  Cells were treated with different formulations at a concentration of 
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120 nM siRNA in serum containing medium at 37 oC for 48 h.  Cells were washed twice with 
PBS and fixed with 1% paraformaldehyde in PBS at room temperature for 15 min. 
Immunostaining was then performed with rabbit anti-mouse AIF (apoptosis inducing factor) 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and goat anti-rabbit IgG conjugated 
with FITC (Fluorescein isothiocyanate) (Santa Cruz Biotechnology, Santa Cruz, CA). Cells 
were mounted with DAPI (4',6-diamidino-2-phenylindole) containing medium (Vectorshield 
®, Vector Lab, Inc. Burlingame, CA) and imaged by a Nikon fluorescence phase contrast 
optical microscope. 
 
3.2.8 Pharmacokinetics (PK) study.  
NCI-H460 cells (5 × 106) were subcutaneously injected into the right flank of nude mice. 
When tumors reached the size of ~1 cm2, mice were i.v. injected with FAM-siRNA in 
different formulations at the dose of 1.2 mg/kg. At different time points, 50-100 μl of blood 
was collected from the tail artery and serum was isolated. Ten microliters of serum was 
mixed with 90 μl of lysis buffer (0.1% sodium dodecyl sulfate in PBS) and incubated at 65 
°C for 10 min, followed by the addition of 200 μl methanol and incubation at 65 °C for 10 
min. The sample was centrifuged at 14,000 rpm for 5 min and 200 μl supernatant was 
transferred to a black 96-well plate (Corning, Corning, NY). The fluorescence intensity of the 
sample was measured by a plate reader (Bioscan, Washington, DC) at λex: 485 nm and λem: 
535 nm. FAM-siRNA concentration in each sample was calculated from a standard curve. 
This extraction method provided 98% recovery of free FAM-siRNA and 48% recovery for 
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FAM-siRNA containing NP. The FAM-siRNA concentration was corrected for the degree of 
sample recovery. 
3.2.9 Tissue distribution and tumor uptake study 
Mice with tumor size of ~1 cm2 were i.v. injected with FAM-siRNA in different formulations 
(1.2 mg/kg). Four h later, mice were killed and tissues were collected and imaged by the 
IVIS Imaging System (Xenogen Imaging Technologies, Alameda, CA). To quantify the 
accumulated doses, the excised tissues were homogenized in 300 or 1,000 μl lysis buffer 
(1,000 μl for livers and 300 μl for others) and incubated at 65 °C for 10 min. One hundred 
microliter of supernatant was collected after centrifugation at 14,000 rpm for 10 min. FAM-
siRNA in the supernatant was extracted and quantified by the method described in the PK 
study. The accumulated dose in each tissue was calculated from a standard curve obtained by 
spiking known amounts of FAM-siRNA or FAM-siRNA containing NP in tissues obtained 
from uninjected animals. Alternatively, tumors were sectioned (7 μm thick) by a cryostat (H/I 
Hacker Instruments & Industries, Winnsboro, SC). Sections were counterstained with DAPI 
and imaged using a Leica SP2 confocal microscope. 
3.2.10 Immunohistochemistry and Western blot 
NCI-H460 xenograft tumor-bearing mice (tumor size ~1 cm2) were i.v. injected with siRNA 
in different formulations (1.2 mg siRNA/kg, one injection per day for 3 days). One day after 
the third injection, mice were killed and tumor samples were collected. Tumors were frozen-
sectioned and 7 μm thick section samples were immunostained with primary antibodies and 
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visualized with kits from Dakocytomation [DakoCytomation Envision + Dual Link System-
HRP (DAB+), DakoCytomation, Carpinteria, CA]. Samples were imaged by using a Nikon 
Microphot SA microscope. The percentage of AIF nuclear localization was calculated based 
on 30 random images obtained from three individual tumors. Total protein (40 μg) isolated 
from the tumors was loaded on a polyacrylamide gel and electrophoresed. Protein bands in 
the gel were then transferred to a polyvinylidene difluoride and the EGFR was probed by 
antibodies. The level of the target proteins in each lysate was detected by enhanced 
chemiluminescence using ChemiGlow (Alpha Innotech, San Leandro, CA) followed by 
detection by the AlphaImager (Alpha Innotech, San Leandro, CA). 
3.2.11 Tumor growth inhibition study.  
NCI-H460 xenograft tumor-bearing mice (size 25-40 mm2) were i.v. injected with siRNA 
containing formulations at the dose of 1.2 mg/kg (one injection per day for 3 days). For the 
chemocombination treatment, cisplatin (3 mg/kg) were intraperitoneally (i.p.) administered 
from the 3rd to 5th day after the first siRNA injection. Tumor growth in the treated mice was 
monitored thereafter. Mouse body weight was also monitored. 
3.2.12 Cytokine induction studies.  
Female athymic nude mice or C57BL/6 mice were injected with siRNA in different 
formulations at the dose of 1.2 mg siRNA/kg. Two h after the injection, blood samples were 
collected and serum was isolated. Tumor necrosis factor, interleukin-6, interleukin- 12 (BD 
Biosciences, San Diego, CA) and interferon-α levels (PBL Biomedical Laboratories, 
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Piscataway, NJ) were measured by enzyme-linked immunosorbent assay according to the 
manufacturer’s protocol. MDM2 (mouse double minute 2) siRNA (target sequence: 5′-
GCUUCGGAACAAGAGACUC-3′) without any known immunostimulatory sequences (5′-
GUCCUUCAA-3′ and 5′-UGUGU-3′) [20,69] was used as a negative control. Calf thymus 
DNA alone was formulated into targeted NPs and injected into the mice at the dose of 2.4 mg 
DNA/kg. This formulation is also regarded as the empty NP (without siRNA). Targeted NPs 
containing EGFR siRNA and luciferase plasmid DNA were also prepared and injected. 
3.2.13 Liver enzyme assay 
Female athymic nude mice of age 6-7 week (Charles River Laboratories) were injected with 
siRNA in different formulations at the dose of 1.2 mg/kg.  Two h after injections, serum 
samples were obtained and the liver enzyme [aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT)] levels were analyzed by Antech Diagnostics. 
3.2.14 Statistical analysis 
All statistical analyses were performed by the one-way ANOVA or a two-tailed student t-test. 
Data were considered statistically significant when P value was less than 0.05. 
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3.3 RESULTS 
3.3.1 PK studies, tissue distribution, and intracellular uptake of siRNA 
Free FAM-siRNA was eliminated rapidly from the blood and the concentration was under 
the detection limit after a 40-minute time point (figure 3.1). In 40 min, only 1% ID of free 
siRNA was detected in the blood. No significant difference in the PK profiles was observed 
between the tumor free and the tumor-bearing mice treated with free siRNA. NP significantly 
prolonged the circulation of siRNA and there was no difference in PK between the targeted 
and nontargeted NPs. NPs showed a rapid distribution phase, in which serum concentrations 
dropped to 1/10 within 40 min. After that, concentrations remained steady for at least 24 h. 
Tumor-bearing mice cleared the NPs from the blood more quickly than the tumor-free mice. 
In 2 min, almost a 100% ID of the NPs remained in the blood of the tumor free mice, while 
only a 25% ID remained in that of the tumor-bearing mice. At the terminal phase (80 min-24 
h), a 5-10% ID was detected in the blood of the tumor free mice, while only 1-2% ID was 
recovered in that of the tumor-bearing mice. The dose recoveries in the major organs of mice 
treated with free siRNA and siRNA in NP were ~30 and 60%, respectively. 
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Figure 3.1 Serum concentration profiles of FAM-siRNA in different formulations. 
Data = mean ± SD, n = 4-8 
 
The PK profiles were fitted with a non-compartment model using the WinNonlin 
program and the key PK parameters were obtained (Table 3.1). For free siRNA, the 
parameters obtained from the tumor free and the tumor-bearing mice were similar to each 
other. NPs significantly increased the terminal phase halflife (t1/2) 80-fold to 100-fold, and 
increased the area under the curve 15-fold to 100-fold and decreased the clearance 15-fold to 
100-fold for siRNA. Again, there was no difference between the parameters of targeted and 
non-targeted NPs. However, the presence of tumor significantly changed some of the 
parameters of the NP. The area under the curve was reduced fourfold to sixfold, the clearance 
was increased fourfold to sixfold, and the steady state volume of distribution (Vss) was 
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increased fivefold to sixfold in the tumor-bearing mice compared to the tumor free mice. The 
t1/2 and mean residence time remained unchanged in the presence of tumor. 
 
Table 3.1 Comparison of pharmacokinetic parameters of FAM-siRNA in different formulations in either 
NCI-H460 xenograft tumor-bearing mice or tumor free micea 
 
 T1/2 (λz)
(h) 
AUC 
(h·µg/ml) 
CL 
(ml/h/kg) 
MRT 
(h) 
Vss 
(ml/kg) 
Free siRNA/tumor-bearing mice 0.29±
0.04
1.08±
0.03
1030.85±
66.5
0.36± 
0.07 
372.34±
63.21
Free siRNA/tumor free mice 0.25±
0
1.17±
0.08
1109.43±
28.65
0.25± 
0.01 
274.21±
17.89
siRNA in non-targeted 
NP/tumor-bearing mice 
27.88±
11.3
16.71±
3.08
73.87±
15.08
37.43± 
16.83 
2609.91±
723.89
siRNA in non-targeted 
NP/tumor free mice 
21.58±
5.98
72.6±
13.73
16.98±
3.56
28.42± 
9.37 
462.12±
89.25
siRNA in targeted NP/tumor-
bearing mice 
20.83±
5.86
15.25±
2.16
79.75±
11.86
27.11± 
6.52 
2127.43±
343.29
siRNA in targeted NP/tumor 
free mice 
31.43±
8.26
98.68±
21.63
12.53±
2.54
43.63± 
11.7 
526.88±
25.25
a The serum concentration profiles (figure 3.1) were analyzed with the WinNonlin program and the key 
parameters were obtained. 
 
 
We employed Xenogen IVIS imaging system to visualize the FAM-siRNA 
distribution in major tissues in the mice 4 h after i.v. injections. As shown in figure 3.2a, 
fluorescence signals were hardly detected in the tissues collected from the mice treated with 
free siRNA. While the liver showed the strongest signal, it was still minimal. Among the 
tissues excised from the mice treated with NP, the NCI-H460 xenograft tumors showed the 
strongest signal and all other tissues showed only background to moderate signals. In the 
quantitative results (figure 3.2b), the liver, lung, and tumor showed comparable uptake of 
free siRNA ranging from 10 to 20% ID/g. Other tissues showed minimal uptake of free 
siRNA (< 5% ID/g). Non-targeted and targeted NP had similar tissue distribution patterns, in 
which 70-80% ID/g accumulated in the tumor, whereas both the lung and liver took up <20% 
ID/g. The uptake of siRNA formulated in NP was under the detection limit in the heart, 
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spleen, and kidney. The bioavailability of siRNA in the tumor tissues was examined by 
confocal microscopy. As shown in figure 3.3 (xyz images), the targeted NP showed strong 
cytosolic delivery of FAM-siRNA, while the non-targeted NP was less efficient in 
intracellular delivery and free siRNA showed no delivery. The percentages of fluorescence 
positive cells for free siRNA, non-targeted NP, and targeted NP were <1%, 5%, and 30%, 
respectively. The distribution of fluorescence in the tumor was heterogeneous. We used z-
axis imaging to further address the intracellular delivery efficiency. Blue arrows indicate the 
extracellular space and pink arrows show the intracellular uptake of FAM-siRNA (figure 3.3 
xzy images). A majority of the siRNA formulated in non-targeted NPs remained in 
extracellular space while the siRNA in targeted NPs was mostly internalized into the cells. 
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Figure 3.2 Tissue distribution study. 
(a) Fluorescence signal of FAM-siRNA in different tissues detected by the Xenogen IVISTM imaging system; 
(b) Tissue distribution of FAM-siRNA in different formulations.  Data = mean ± SD, n = 3-4. 
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Figure 3.3 Tumoral uptake of FAM-siRNA in different formulations. 
Blue arrows indicate the extracellular space and pink arrows indicate the intracellular uptake of FAM-siRNA.  
Magnification = 400X (xyz images), 630X (xzy images) 
3.3.2 EGFR gene silencing, apoptosis induction, and tumor growth inhibition 
To examine the biological activities of siRNA, EGFR levels in the tumor were detected by 
immunohistochemistry (figure 3.4a upper) and Western blot analysis (figure 3.5). The 
EGFR in NCI-H460 tumor was silenced by siRNA in targeted NPs. The non-targeted NPs 
showed only a partial effect, whereas free siRNA and the control siRNA in targeted NPs 
showed no effect. We also examined the apoptotic markers in the tumor (figure 3.4a middle 
and bottom). Prostate apoptotic response 4 levels were elevated after the treatment of siRNA 
in targeted NPs, while siRNA in non-targeted NPs showed only a moderate effect. Other 
control treatments had little effect. Immunostaining of the AIF showed similar results, in 
which siRNA in targeted NPs induced significant nuclear translocation of AIF (figure 3.4a 
bottom, P < 0.01). We calculated the percentage of AIF nuclear translocation to quantify the 
percentage of apoptosis. Tumor apoptosis in mice treated with PBS, free siRNA, siRNA in 
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non-targeted NPs, siRNA in targeted NPs, and control siRNA in targeted NPs were 2, 3, 7, 
15, and 3%, respectively (figure 3.4b). Three injections of siRNA in targeted NPs showed a 
partial inhibition of tumor growth  similar to that of i.p. cisplatin (figure 3.6). However, 2 
weeks later, the tumor growth rate became comparable to the untreated control. Other control 
treatments had no effects. Combination of siRNA (formulated in targeted NP) and cisplatin 
completely inhibited tumor growth for an entire week. Tumor growth, however, resumed 
after 1 week. 
 
Figure 3.4 Immunohistochemical analysis of the tumor samples. 
(a) Immunohistochemical staining on tumor sections: EGFR, PAR-4, and AIF. Magnification = 200X. (b) 
Quantitative analysis of nuclear translocation of AIF in the tumors treated with different formulations.  ** 
indicates p<0.01, * indicates p<0.05 
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Figure 3.5 Western blot analysis of EGFR in the NCI-H460 xenograft tumor after treatment with 
different formulations. 
 
 
 
Figure 3.6 NCI-H460 xenograft tumor growth inhibition by siRNA in different formulations with or 
without the combination of cisplatin.   
Solid arrows indicate the i.v. administrations of siRNA (1.2 mg/kg) and dash-line arrows indicate the i.p. 
injections of cisplatin (3 mg/kg).  Data = mean ± SD, n = 6-9. * indicates p<0.05, ** indicates p<0.01 
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3.3.3 Toxicity and immune response studies in normal mice 
As shown in figure 3.7a, siRNA alone (group B) or when formulated with calf thymus DNA 
into NPs induced a very mild production of inflammatory cytokines in the athymic nude mice 
(groups C-E). However, when plasmid DNA was co-formulated with siRNA (group G), the 
formulation became very immunogenic. In the C57BL/6 mice model (figure 3.7b), free 
siRNA (group B) did not induce cytokine production, while siRNA formulated in NPs 
(groups C and D) induced a significant production of all analyzed cytokines, except for the 
tumor necrosis factor. Targeted NPs (group D) induced higher levels of cytokines compared 
to the non-targeted formulation (group C). Unexpectedly, targeted NPs containing MDM2 
siRNA (with no identifiable immunostimulatory motifs, group E) induced significantly 
higher levels of cytokines than the one containing EGFR siRNA (group D). Empty NP 
(group F) showed very mild immunotoxicity. When using plasmid as the carrier DNA in the 
targeted NP formulation (group G), all inflammatory cytokines were induced to high levels. 
Additionally, serum levels of AST and ALT in mice treated with siRNA in different 
formulations were all in the normal range (figure 3.8). Mouse body weight did not change 
significantly during the siRNA treatment (figure 3.9). 
 56
 
Figure 3.7 Serum cytokine analysis. 
Serum cytokine levels in the athymic nude mice (a) and C57BL/6 mice (b) 2 h after the injection of different 
formulations at the dose of 1.2 mg siRNA/kg (2.4 mg DNA /kg for group F).  A, PBS; B, EGFR siRNA in PBS; 
C, EGFR siRNA and calf thymus DNA in non-targeted NP; D, EGFR siRNA and calf thymus DNA in targeted 
NP; E, MDM2 siRNA and calf thymus DNA in targeted NP; F, calf thymus DNA in targeted NP (empty NP); 
G, EGFR siRNA and plasmid DNA in targeted NP.  Data = mean ± SD, n = 3-8. 
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Figure 3.8 Serum ALT and AST analysis. 
Serum ALT and AST levels in the mice 2 h after the treatment of PBS or siRNA in different formulations at the 
dose of 1.2 mg/kg.  Data = mean ± SD, n = 4. 
 
 
 
 
 
 
Figure 3.9 Mouse body weight during the treatment of different siRNA formulations. 
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3.4 DISCUSSION 
In the in vitro preliminary studies, we showed that the targeted NP delivered a significantly 
higher amount of siRNA into NCI-H460 cells and showed a stronger gene silencing effect 
compared to non-targeted NP (figure 3.10). Targeted NP silenced the EGFR at the 
concentration of 120 nM (figure 3.10b). The cytotoxicity of the NP was siRNA sequence 
and formulation dependent (figure 3.11). The cell death mechanism was confirmed to be 
apoptosis by means of immunostaining of the apoptosis inducing factor (AIF) (figure 3.11b). 
 
 
Figure 3.10 In vitro cellular uptake and gene silencing analysis 
(a) Fluorescence photographs of NCI-H460 cells after treatment with FAM-siRNA in non-targeted NP or 
targeted NP at the conc. of 320 nM for 4 h. Magnification = 200X. (b) Western blot analysis of NCI-H460 cells 
after treatment with siRNA in different formulations at the conc. of 120 nM for 48 h 
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Figure 3.11 In vitro cytotoxicity assay 
(a) Flow cytometry analysis of NCI-H460 cells after treatment with different formulations at the conc. of 320 
nM siRNA for 48 h.  Cells were stained with propidium iodide and analyzed for dead population. (b) 
Immunocytochemical analysis of AIF nuclear translocation of NCI-H460 cells after treatment with different 
formulations at the conc. of 120 nM siRNA for 48 h.  Arrows indicate the nuclear translocation of AIF.  
Magnification = 200X. 
 
The PK results suggest that the majority of the free siRNA was eliminated from the 
blood before it accumulated in the tissues. On the other hand, the tumor appeared to be the 
major uptake tissue for NPs and contributed a high uptake (70-80% ID/g) (figure 3.2b). 
Additionally, the liver and lung only took up 10-20% ID/g, which shows the high tumor 
selectivity of the NPs. The high tissue-selective delivery and tumor accumulation of the 
PEGylated NPs (with or without ligand) were probably due to the improved EPR effect, 
which was resulted from the high degree of PEG coating.  As shown in the Chapter 2, 
approximately 10.6 mol% of the outer leaflet of the supported lipid bilayer was modified 
with DSPE-PEG. Normally, when DSPE-PEG is introduced to a regular lipid bilayer, the 
permeability of which is increased, resulting in the release of encapsulated drugs [40]. 
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Therefore, 5 mol% of PEGylation is a common formulation for liposomes containing a 
regular bilayer in the compromise of surface protection and low membrane permeability. In 
the case of our NP formulation, the siRNA was complexed with protamine, and was further 
coated with a supported bilayer stabilized by the charge-charge interaction.  Therefore, the 
bilayer could tolerate a high degree of PEGylation (10.6 mol%) with a full protection of the 
particle surface, leading to the much improved EPR effect. 
The increase of Vss for NPs in the tumor-bearing mice as compared to that of the 
tumor free mice suggests that the tumor served as a distribution sink for NPs. The decrease in 
the area under the curve and increase in clearance are also consistent with this observation. 
The presence of the targeting ligand facilitated the internalization of siRNA by the tumor 
cells (figure 3.3) but did not alter the PK (figures 3.1 and 3.2). The results indicate that 
extravasation of the vector, which was mainly dependent on the enhanced permeability and 
retention effect, was the rate limiting factor. Enhanced intracellular uptake of the vector did 
not cause further clearance. The internalization of siRNA formulation in the tumor was 
uneven (figure 3.3), suggesting that cells closer to the angiogenic capillaries are likely to 
take up more siRNA. However, the EGFR silencing in the entire tumor was nearly complete 
(figures 3.4a upper and 3.5). This suggests only small amounts of siRNA, as long as 
properly delivered, are necessary for effective gene silencing. The in vivo RNA interference 
effect was highly dependent on the formulation and siRNA sequence. Only siRNA 
formulated in targeted NPs showed significant gene silencing activity (figures 3.4a upper 
and 3.5). This targeted formulation also showed good efficiency in inducing apoptosis in the 
tumor (15%, P < 0.05) (figure 3.4b), inhibiting tumor growth (~40%, P < 0.01 on day 10) 
and sensitizing the tumor to chemotherapy (figure 3.6).  
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The cytokine induction effect was dependent on the model, formulation, and siRNA 
sequence. The results in figure 3.7a showed that the immune response of the nude mice were 
not sensitive to siRNA but to unmethylated CpG motifs. siRNA-mediated immune response 
is via toll-like receptor 7/8 (TLR7/8) [70,71], suggesting that the toll-like receptor 7/8 may be 
not be expressed or only at a low level in the nude mice. On the other hand, the toll-like 
receptor 9 was shown to be a good immunostimulatory target by CpG oligonucleotides in 
nude mice [72], and, therefore, a formulation containing plasmid showed strong 
immunotoxicity (figure 3.7a). In the C57BL/6 model, when siRNA was formulated into the 
NP, the immunostimulatory effect was strengthened (figure 3.7b). Additionally, the presence 
of the targeting ligand in the formulation increased the immunotoxicity of siRNA. This is 
probably due to the increased cellular uptake through endosomal pathway. Surprisingly, 
MDM2 siRNA containing no identifiable inflammatory sequences induced higher levels of 
cytokines than EGFR siRNA containing the immunostimulatory sequence (5′-UGUGU-3′) 
(figure 3.7b). MDM2 siRNA may contain some unknown, yet potent, sequences that induced 
the production of cytokines. Another possibility is that different toll-like receptor isoforms 
might be involved in the immunostimulatory effect of MDM2 siRNA, which is suggested by 
Wang and colleagues [73]. More importantly, empty NP (group F) showed very mild 
immunotoxicity (figure 3.7a and b), suggesting the carrier itself was safe. Although several 
siRNA delivery systems have exhibited high activity against tumors in vivo [2-
4,12,19,24,43-51], our NP formulation provides the advantages of an almost complete 
encapsulation efficiency (>90%), the highest tumor delivery efficiency so far reported (70–
80% ID/g at 4 h) (figure 3.2b) and relatively easy preparation. Our carrier also showed low 
toxicity (figure 3.7, 3.8 and 3.9). 
4.0  EFFICIENT GENE SILENCING IN METASTATIC TUMOR BY SIRNA 
FORMULATED IN SURFACE-MODIFIED NANOPARTICLES 
We have developed a nanoparticle (NP) formulation for systemically delivering siRNA into 
metastatic tumors. The NP, composed of nucleic acids, a polycationic peptide and cationic 
liposome, was prepared in a self-assembling process. The NP was then modified by PEG-
lipid containing a targeting ligand, anisamide, and thus was decorated for targeting sigma 
receptor expressing B16F10 tumor. The activity of the targeted NP was compared with the 
naked NP (no PEGylation) and non-targeted NP (no ligand). The delivery efficiency of the 
targeted NP was 4-fold higher than the non-targeted NP and could be competed by excess 
free ligand. Luciferase siRNA was used to evaluate the gene silencing activity in the B16F10 
cells, which were stably transduced with a luciferase gene. The in vitro gene silencing 
activity of the targeted NP was significantly higher than the other formulations and lasted for 
4 days. While confocal microscopy showed the naked NP provided no tissue selectivity and 
nontargeted NP was ineffective for tumor uptake, the targeted NP effectively penetrated the 
lung metastasis, but not the liver. It resulted in 70-80% gene silencing in the metastasis 
model after a single i.v. injection (150 μg siRNA/kg). This effective formulation also showed 
very little immunotoxicity. 
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4.1 INTRODUCTION 
siRNA has become a potential alternative for treating multi-drug resistant metastasis, which 
is the major cause of death in cancer patients [74]. Selective delivery of siRNA to metastatic 
tumors remains a major obstacle for siRNA based therapy. Although various delivery 
systems for siRNA have been developed, only a few successful cases have been reported on 
delivering siRNA into metastatic tumor [4,12,24,49,75]. Between viral and non-viral vectors, 
non-viral delivery offers several advantages, such as high tissue selectivity and low 
immunotoxicity [23]. In the Chapter 2 and 3, we have shown that the NP containing a 
supported lipid bilayer could be surface-modified with a high amount of PEG (10.6 mol%) 
by post-inserting DSPE-PEG. A complete shielding of the NP surface was found with a 
neutral zeta potential (-5.6 ± 4.5 mV) and abolishment of non-specific uptake in the liver.  In 
the Chapter 3, this highly PEGylated NP delivered 70-80% injected dose/g into the tumor, 
inducing a significant gene silencing and antitumor activity.  The data suggest that the NP 
having full surface protection showed improved EPR effect for solid tumor delivery. Here, 
we investigated the efficiency of the NP for delivering siRNA into an experimental 
metastatic tumor model, B16F10 lung metastasis in C57BL/6 mice. The cells were stably 
transduced with luciferase gene by using a retroviral vector before introduction to the 
animals. siRNA against luciferase was used in this study for the assessment of the gene 
silencing effect. We also compared the activities of different siRNA formulations, including 
free siRNA, naked NP (no PEGylation), non-targeted NP (PEGylated but without ligand) and 
targeted NP (PEGylated with ligand). 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
DOTAP, cholesterol, and DSPE-PEG2000 were purchased from Avanti Polar Lipids, Inc. 
(Alabaster, AL). Protamine sulfate (fraction X from salmon) and calf thymus DNA (for 
hybridization, phenol-chloroform extracted and ethanol precipitated) were from Sigma-
Aldrich (St. Louis, MO). DSPE-PEG2000-anisamide (DSPE-PEG-AA) was synthesized in 
our lab using the methods described previously [53]. 
Anti-luciferase siRNA (GL3) (target sequence 5'- CTT ACG CTG AGT ACT TCG A 
-3') was purchased from Dharmacon (Lafayette, CO) in deprotected, desalted, annealed form. 
For in vitro quantitative and tissue distribution studies, fluorescein (FAM) and cy3 labeled 
siRNA (3’ end of the sense strand) provided by Dharmacon were used.  
B16F10 cells, murine melanoma cells, were obtained from the American Type Cell 
Collection and were stably transduced with GL3 firefly luciferase gene using a retroviral 
vector in Dr. Pilar Blancafort’s lab at the University of North Carolina at Chapel Hill (UNC). 
The cells were maintained in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 
10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA). B16F10 cells expressing sigma 
receptors [76] were used as model cells in our study. 
 65
4.2.2 Experimental animals 
Female C57BL/6 mice of age 6-8 week (16-18 g) were purchased from Charles River 
Laboratories (Wilmington, MA). All work performed on animals was in accordance with and 
approved by the IACUC committee at UNC. 
4.2.3 Preparation of siRNA containing nanoparticles 
Nanoparticles (NP) were prepared as previously described in the Chapter 2.  The 
formulations were used without further purification. 
4.2.4 In vitro cellular uptake study 
B16F10 cells (1 × 105 cells/0.5 ml/well) were seeded in 24-well plates (Corning Inc., Corning, 
NY) 20 h before experiments. Cells were treated with different formulations containing 500 
nM FAM-siRNA in the culture medium at 37°C for 4 h. Cells were washed three times with 
PBS followed by incubation with 300 μl lysis buffer (0.3% Triton X-100 in PBS) at 37°C for 
0.5 h. Fluorescence intensity of 100 μl cell lysate was determined by a plate reader (λex: 485 
nm, λem: 535 nm) (PLATE CHAMELEON Multilabel Detection Platform, Bioscan Inc., 
Washington, DC). For free ligand competition study, cells were co-incubated with 50 μM 
haloperidol with different formulations. 
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4.2.5 In vitro luciferase gene silencing study 
B16F10 cells (5 x 105 cells/5 ml/flask) were seeded in 25T culture flasks (Becton Dickinson 
Co., Franklin Lakes, NJ) 20 h before experiments. Cells were treated with different 
formulations at a concentration of 250 nM siRNA in DMEM containing 10% FBS at 37°C 
for 24 h. Cells were trypsinized and 2 x 105 cells were collected for luciferase activity assay 
and the rest of cells were re-cultured in a 25T culture flask for the assay of the next time 
point. Collected cell pellets were incubated with 100 μl lysis buffer (0.05% Triton X-100 and 
2 mM EDTA in 0.1 M Tris-HCl) at room temperature for 10 min. Ten microliter lysate was 
mixed with 100 μl substrate (Luciferase Assay System, Promega Co., Madison, WI) and the 
luminescence was measured by a plate reader. The protein concentrations of the samples 
were determined by using a protein assay kit (Micro BCATM protein assay kit, Pierce). 
Luciferase activity of a sample was normalized with the protein content and expressed as 
percent luminescence intensity compared to the untreated control. Percent luciferase activity 
of cells treated with different formulations was plotted against the time. The AAC (area 
above the curve) of different formulations was calculated and compared with each other. 
AAC = AUC (area under the curve)untreated – AUCtreated. 
4.2.6 Tissue distribution study 
C57BL/6 mice were injected with 2 x 105 B16F10 cells via the tail vein. Seventeen days later, 
mice were i.v. injected with cy3-siRNA formulated in PBS, naked NP, non-targeted NP or 
targeted NP at the dose of 1.2 mg/kg. After 4 h, mice were euthanized and major tissues were 
collected. Paraffin embedded tissue sections of 5 μm in thickness were prepared. Sections 
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were re-hydrated, mounted with the DAPI containing medium (Vectashield®, Vector 
Laboratories Inc., Burlingame, CA) and imaged using a Leica SP2 confocal microscopy. 
4.2.7 Immunohistochemistry 
B16F10 metastasis loaded lungs and normal lungs from C57BL/6 mice were collected for the 
preparation of paraffin embedded sections (5 μm thick). Sigma receptor expression in the 
sections was stained by using the rabbit anti-mouse sigma receptor antibody (Santa Cruz 
Biotechnologies) and a kit (mouse-to-mouse detection system, Chemicon International, 
Temecula, CA). Tissue sections were counter stained with hematoxylin for nuclei, mounted 
and imaged using a Nikon phase contrast light microscopy. 
4.2.8 In vivo gene silencing study 
C57BL/6 mice were i.v. injected with 2 x 105 B16F10 cells via the tail vein. Seventeen days 
later, mice were given i.v. injections of anti-luciferase siRNA at the dose of 150 μg/kg 
formulated in PBS, naked NP, non-targeted NP or targeted NP. Control siRNA (target 
sequence: 5’-AATTCTCCGAACGTGTCACGT-3’) [67] formulated in targeted NP was also 
prepared to verify if the silencing effect was sequence dependent. For the dose-response 
study, tumor bearing mice were i.v. injected with siRNA in targeted NP at doses of 18.75, 
37.5, 75, 150, 300, 600 and 1,200 μg/kg. After 48 h, mice were euthanized and the tumor 
loaded lungs were collected. The lung was homogenized in 1 ml lysis buffer (0.05% Triton 
X-100 and 2 mM EDTA in 0.1 M Tris-HCl) followed by centrifugation at 5,000 rpm for 5 
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min. Ten μl supernatant was mixed with 100 μl luciferase substrate and the luciferase activity 
was measured by a plate reader. 
4.2.9 Cytokine induction assay 
C57BL/6 mice were i.v. injected with anti-luciferase siRNA formulated in PBS, naked NP, 
non-targeted NP and targeted NP at the dose of 150 μg/kg. Targeted NP formulated with 
plasmid DNA (pNGVL-Luc prepared by Bayou Biolabs) [77] instead of calf thymus DNA 
was prepared and used as a positive control for the evaluation of immunotoxicity of calf 
thymus DNA. Two h after the injections, blood samples were collected from the tail artery 
and allowed to stand at room temperature for 0.5 h for coagulation. Serum was obtained by 
centrifuging the clotted blood at 16,000 rpm for 20-40 min. Cytokine levels were determined 
by using ELISA kits for TNF, IL6, IL12 (BD Biosciences, San Diego, CA) and IFN-α (PBL 
Biomedical Laboratories, Piscataway, NJ). 
4.2.10 Statistical analysis 
Data are presented as the mean ± SD. The statistical significance was determined by using 
the analysis of variance (ANOVA). P values of <0.05 were considered significant. 
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4.3 RESULTS 
4.3.1 Characterization of NP 
The characteristics of the NP are summarized in table 4.1. The particle sizes of the three NP 
formulations were similar to each other. DSPE-PEG modification significantly reduced the 
zeta potential of the NP. Targeted NP showed a slight increase in the zeta potential compared 
to the non-targeted NP.  It is noted that the formulations were not further purified. 
 
Table 4.1 Characterization of nanoparticle formulations 
 Naked NP Non-targeted NP Targeted NP 
 
Particle size (nm) 117.6 ± 13.2 115.1 ± 14.8 110.6 ± 13.8 
 
Zeta potential (mV) 43.2 ± 3.62 20.4 ± 2.08 25.51 ± 1.22 
 
Data are representative data from repeated measures of 4-5 samples. 
4.3.2 In vitro cellular uptake 
To investigate the delivery efficiency of our NP formulations, we performed the cellular 
uptake study using FAM labeled siRNA. The fluorescence intensity of the cell lysate 
represents the intracellular delivery efficiency for siRNA by a given formulation. As shown 
in figure 4.1, cell lysate from cells treated with free FAM-siRNA showed background 
fluorescence, while those from cells treated with NP formulations had significantly higher 
fluorescence intensities. After PEGylation, the delivery efficiency of non-targeted NP was 
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significantly reduced to 1/10 compared to the naked NP. However, targeted NP showed 4-
fold increased delivery efficiency compared to non-targeted NP. The addition of free 
haloperidol, a known agonist for sigma receptors, significantly reduced the delivery 
efficiency of targeted NP but not other formulations. 
 
Figure 4.1 Fluorescence intensities of cell lysate from cells treated with FAM-siRNA containing 
formulations. 
B16F10 cells were incubated with different formulations at 37°C for 4 h in the absence or presence of 50 μM 
haloperidol.  Cells were washed and lysed.  Cell lysate was analyzed for fluorescence intensity by a plate 
reader.  Data = mean ± SD (n=3), * indicates p<0.05. 
4.3.3 In vitro luciferase gene silencing 
We examined both the extent and the duration of the gene silencing effect by siRNA in 
different formulations. As shown in figure 4.2, free siRNA showed minimal effect, while the 
NP formulations had moderate to strong gene silencing effect (p<0.05 compared to free 
siRNA). siRNA formulated in the naked NP and the targeted NP had 2-2.5 fold higher 
activity than in the non-targeted NP (p<0.05). The gene silencing effect decreased right after 
the dosing stopped for the naked NP, while the targeted NP showed a prolonged activity for 4 
days. Therefore, the overall activity (AAC) of the targeted NP was significantly higher than 
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the naked NP (p<0.05). Control siRNA formulated in the targeted NP showed moderate but 
very transient effect and the overall effect (AAC) was not significantly higher than that of the 
free siRNA (p>0.05). 
 
Figure 4.2 In vitro luciferase gene silencing effect of different siRNA formulations (A) and the AAC (area 
above the curve) of different formulations in figure 4.2A (B). 
B16F10 cells were incubated with different siRNA formulations at 37°C for 24 h.  At the end of incubation, 
formulations containing medium was removed and cells were washed.  Luciferase activities of the cells (2 x 
105) were analyzed at different time points after the treatment.  Data = mean ± SD (n=3), * indicates p<0.05 
compared to the free siRNA. 
4.3.4 Tissue distribution of cy3-siRNA 
Tissue distribution study was performed to evaluate the in vivo tumor delivery by different 
NP formulations. Free cy3-siRNA showed poor tissue accumulation in both tumor free and 
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tumor loaded lungs, as very little cy3 signal was detected in the sections (figure 4.3A). 
Naked NP effectively delivered cy3-siRNA to the lung alveolar cells, but showed relatively 
poor penetration into the tumor nodules. Non-targeted NP showed poor tissue uptake in both 
tumor free and tumor loaded lungs. On the other hand, targeted NP provided the highest 
tumor penetration and uptake among the four formulations. Other normal organs (heart, 
spleen and kidney) only showed minimal fluorescence signal except liver. As shown in 
figure 4.3B, naked NP showed significant liver accumulation at 4 h in both tumor free and 
tumor bearing mice. However, PEGylated NP (with or without ligand) only accumulated in 
the liver of tumor free mice but not tumor bearing mice at 4 h. Liver uptake of free cy3-
siRNA was very little in both tumor free and tumor bearing mice. 
4.3.5 Immunohistochemistry of sigma receptor 
Tissue distribution results indicated that the tissue surrounding the tumor significantly 
contributed to uptake of the targeted NP in the tumor loaded lung. To address if the uptake of 
targeted NP was associated with the presence of small B16F10 metastasis, we performed 
immunostaining of the sigma receptor on the lung tissues. Brown staining in the tissue 
section indicated the expression of sigma receptor, while nuclei were counter stained blue by 
hematoxylin. As shown in figure 4.3C, sigma receptor was expressed in a significantly 
higher level in the B16F10 tumor cells and the surrounding tissue than that in the normal 
lung, which only showed a basal level (figure 4.3C). 
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Figure 4.3 Confocal microscopy photographs of the lungs (A) and livers (B) collected from the tumor free 
(a) and B16F10 tumor bearing mice (b). 
Mice were i.v. injected with cy3-siRNA in different formulations.  After 4 h, mice were sacrificed and major 
tissues were collected and processed for paraffin embedded sections.  Tissue sections were re-hydrated, 
mounted with the DAPI containing medium and imaged by confocal microscopy.  Pictures are the overlay of 
phase contrast, DAPI fluorescence signal (blue, nuclei) and cy3 signal (red, siRNA). T and L indicate the 
presence of tumor and lung tissue, respectively.  Magnification = 400x.  C, immunohistochemistry of sigma 
receptor in tumor loaded lung (a) and tumor free lung (b).  T and L indicate the presence of tumor and lung 
tissue, respectively.  Arrows indicate the presence of B16F10 cells.  Magnification = 200 x 
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4.3.6 In vivo luciferase gene silencing 
The in vivo activity of the NP formulations was assessed by the luciferase gene silencing in 
the whole B16F10 tumor loaded lungs. Figure 4.4A shows the activity of siRNA in different 
formulations. The luciferase activity was compared with the untreated control. siRNA in PBS, 
naked NP, non-targeted NP and targeted NP silenced 0%, 50%, 10% and 75% luciferase 
activity, respectively (figure 4.4A). Only the naked NP and the targeted NP showed a 
significant effect (figure 4.4A, p<0.05). Control siRNA formulated in the targeted NP had no 
effect. Figure 4.4B indicates that ED50 of the targeted NP formulation was 75 μg/kg. The 
optimal dose for the maximum gene silencing effect (70-80%) was 150 μg/kg, and further 
increase of the dose did not result in a higher activity (figure 4.4B). 
4.3.7 Cytokine induction study 
The immunotoxicity of the NP formulations was monitored by measuring the serum 
concentrations of proinflammatory cytokines 2 h after injections (figure 4.5). None of the NP 
formulations composed of calf thymus DNA induced significant production of the 
proinflammatory cytokines (IL6, IL12, TNF and IFN-α). The targeted NP formulated with 
plasmid DNA, however, was very immunotoxic 
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Figure 4.4 In vivo luciferase gene silencing effect of different siRNA formulations at the dose of 150 μg/kg 
(A) and that of the targeted NP at various doses (B). 
B16F10 tumor bearing mice were i.v. injected with different siRNA formulations.  After 48 h, mice were 
sacrifice and the tumor loaded lungs were excised for the luciferase activity assay.  Luciferase activity was 
compared to the untreated control and expressed as % luciferase activity.  Data = mean ± SD (n=3-8), * 
indicates p<0.05 compared to the untreated control. 
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Figure 4.5 The serum cytokine concentrations of the mice 2 h after the i.v. injections of siRNA in 
different formulations. 
C57BL/6 mice were i.v. injected with different siRNA formulations (A, untreated; B, siRNA in PBS; C, siRNA 
and calf thymus DNA in naked NP; D, siRNA and calf thymus DNA in non-targeted NP; E, siRNA and calf 
thymus DNA in targeted NP; F, siRNA and plasmid DNA in targeted NP.  After 2 h, blood was collected from 
the tail artery and serum concentrations of the cytokines were analyzed by the ELISA method.  Data = mean ± 
SD (n=4), * indicates p<0.05 compared to the untreated control. 
4.4 DISCUSSION 
This highly positively charged NP formulation (naked NP, zeta potential ~40 mV) tends to 
aggregate when incubated with high salt buffer or serum [33] and had strong charge-charge 
interaction with the cells. Surface PEGylation offered steric hindrance for the NP, which 
stabilized the formulation in the serum containing medium [33] but also reduced the 
association with the cells (figure 4.1). A targeting ligand (anisamide) tethered to the end of 
PEG retargeted the NP to the sigma receptor expressing cells (figure 4.1 and [33]), which 
was partially inhibited by the presence of free haloperidol, a known agonist for the receptor. 
 77
Although the zeta potential of the targeted NP was slightly higher than that of the non-
targeted NP due to the positively charged anisamide ligand, the targeted NP did not show 
increased delivery efficiency for sigma receptor negative cells (CHO and CT26 cells, data 
not shown). Additionally, neither the non-targeted nor the targeted NP formed aggregates 
with the FBS [33]. The data suggest that the PEGylated NPs (with or without ligand) were 
sterically stabilized by the PEG coating and the entry mechanism for the targeted NP was via 
a sigma receptor dependent pathway. 
The in vitro gene silencing effect of different formulations showed high correlation 
with the siRNA sequence and the intracellular delivery efficiency (figure 4.2). When anti-
luciferase siRNA was formulated into NP formulations, the gene silencing activity was 
significantly improved (p<0.05, figure 4.2B) due to the enhanced intracellular delivery 
(figure 4.1). Interestingly, targeted NP providing lower delivery efficiency (figure 4.1) 
showed higher gene silencing activity than the naked NP (figure 4.2B). It is also noted that 
the silencing activity of targeted NP was significantly prolonged for 4 days, while that of 
naked NP was relatively transient (figure 4.2A). First, the delivery efficiency was 
determined at 4 h, which favors the naked NP that entered into the cells via a strong charge-
charge interaction. Targeted NP, on the other hand, delivered siRNA through a receptor 
mediated pathway, which is dependent on the receptor recycling/trafficking that usually takes 
longer time but is a continuous process. For a short half-life drug such as siRNA, continuous 
input of drugs often results in enhanced therapeutic effect. Second, naked NP formed 
aggregates before internalization and siRNA release from aggregates could be slow, which 
would result in a reduced bioavailability. Targeted NP did not form aggregates with serum 
and the intracellular release of siRNA should be faster and more complete, leading to a 
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prolonged gene silencing effect. Although the control sequence showed only very transient 
activity, which was probably due to an off-target effect, the overall activity was not 
significantly higher than that of the free siRNA (figure 4.2B). The result indicated that the 
gene silencing activity was highly sequence dependent. 
The in vivo activity results are consistent with the in vitro observation, in which the 
targeted NP showed significantly higher activity (70-80% gene silencing) than other 
formulations (figure 4.4A). The enhanced activity of the targeted NP was mainly due to the 
significantly improved tumor uptake as shown in figure 4.3A (panel b). Naked NP having 
poor tumor tissue penetration (panel b of figure 4.3A) provided only 50% gene silencing 
(figure 4.4A), which was probably resulted from the formation of large aggregate when i.v. 
injected. Other formulations, including free siRNA, non-targeted NP and control siRNA in 
targeted NP, had little effect (figure 4.4A, p>0.05). Again, the results suggested that 
significant gene silencing activity was highly dependent on the correct siRNA sequence and 
sufficient tumor delivery.  
Naked NP delivered siRNA via a non-specific charge-charge interaction mechanism. 
As shown in figure 4.3, siRNA formulated in the naked NP accumulated in the lung, tumor 
and liver with little selectivity. The tissue uptake was particularly significant in the lung, the 
first pass organ for i.v. injection. Non-targeted NP, however, showed little lung uptake due to 
the steric hindrance provided by PEG (figure 4.3A). In the tumor free mice, the liver 
appeared to be the major organ for eliminating the PEGylated NP (with or without ligand) 
(figure 4.3). Nevertheless, the liver uptake of the PEGylated NP was significantly reduced in 
the tumor bearing mice (panel b of figure 4.3B), which was probably due to the kinetic 
competition of the uptake by the tumor (panel b of figure 4.3A). In other words, in the tumor 
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bearing mice, PEGylated NP effectively accumulated in the tumor by the EPR effect 
(enhanced permeability and retention) [78], resulting in a reduced liver uptake. It is noted 
that confocal microscopy only showed the intracellularly delivered and released cy3-siRNA 
signal. Signal of cy3-siRNA that were compactly formulated in NP and accumulated 
extracellularly was quenched and therefore, could not be shown in figure 4.3A (panel b). Our 
previous results suggest that PEGylated NP delivered comparable amount of siRNA to the 
tumor tissue but only targeted NP showed significant intracellular delivery [8]. Again, the 
improved metastatic tumor delivery via the PEGylated NP may be due to the improved 
stability mediated through the highly PEGylated supported lipid bilayer on the NP surface.  It 
is anticipated that the tumor nodules in the lung (17 days after tumor inoculation) were big 
enough to allow the PEGylated NP to accumulate via the EPR effect in this study. As shown 
in figure 4.3C, normal lung expressed a basal level of sigma receptor and therefore, the 
targeted NP showed enhanced uptake in the lung compared to the non-targeted NP (figure 
4.3A). Additionally, the surrounding tissue around the tumor contained small amounts of 
B16F10 cells (figure 4.3C, as indicated by the arrows), which also contributed to the 
significant uptake of the targeted NP. The enhanced uptake of the targeted NP in the 
surrounding tissue may be via these metastatic cells, which were closer to the blood supply 
and more accessible compared to the cells in the large tumor nodules.  
The toxicity of the NP formulations was evaluated by their induction of the 
proinflammatory cytokines (IL6, IL12, TNF, IFN-α) (figure 4.5). At such a low dose (150 
μg/kg), none of the NP formulations were immunotoxic. Additionally, no body weight 
decrease was observed for any of the mice treated with the formulations (data not shown). 
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To summarize, free siRNA could hardly penetrate through the cell membrane (figure 
4.1) due to its highly hydrophilic nucleic acid backbone. Therefore, siRNA itself with low 
bioavailability showed no gene silencing activity (figures 4.2 and 4.4). Encapsulation of 
siRNA into the naked NP dramatically increased the intracellular delivery and the gene 
silencing activity (figures 4.1, 4.2 and 4.4) through the charge-charge interaction of the 
formulation with cells. However, the non-specific nature of the charge charge interaction 
resulted in the formation of large aggregates when injected into the blood [30] and low tissue 
selectivity (figure 4.3). PEGylation of the naked NP abolished the non-specific interaction 
with negatively charged cells or proteins [33] but also reduced the cellular and tissue uptake 
(figures 4.1 and 4.3), resulting in low silencing activity (figures 4.2 and 4.4). Introduction 
of a targeting ligand at the distal end of PEG chain restored the intracellular delivery to the 
sigma receptor positive cells (figures 4.1 and 4.3), while the tissue selectivity was 
maintained (figure 4.3). This targeted NP formulation with improved tissue specificity and 
delivery efficiency silenced the luciferase gene in the lung metastasis effectively (figure 4.4) 
without any significant immunotoxicity (figure 4.5). 
4.5 CONCLUSIONS 
We have developed a surface-modified NP formulation that selectively delivered siRNA to 
the sigma receptor expressing B16F10 lung metastasis. With high delivery efficiency, a low 
dose (150 μg/kg) was required to achieve 70-80% gene silencing in the whole lung 
metastasis. This targeted NP formulation also showed little immunotoxicity, which promises 
its potential use for metastasis treatment. 
5.0  EFFICIENT ONCOGENE SILENCING AND METASTASIS 
INHIBITION VIA SYSTEMIC DELIVERY OF SIRNA 
Selective delivery of siRNA to metastatic tumor remains challenging.  We have developed a 
nanoparticle (NP) formulation composed of siRNA, a carrier DNA, a polycationic peptide 
and cationic liposomes.  The NP was obtained by a self assembling process, followed by 
surface modification with a PEG conjugated ligand, anisamide.  Thus, the NP was PEGylated 
and a ligand was presented to target sigma receptor expressing murine melanoma cells, 
B16F10.  The lung metastasis model was established by i.v. injecting the B16F10 cells into 
the C57BL/6 mice.  A mixture of siRNA against MDM2, c-myc and VEGF co-formulated in 
the targeted NP caused simultaneous silencing of each oncogene in the metastatic nodules.  
Two consecutive i.v. injections of siRNA in the targeted NP significantly reduced 
approximately 70-80% of the lung metastasis at a relatively low dose (0.45 mg/kg), while 
free siRNA and the non-targeted NP showed little effect.  This targeted NP formulation 
significantly prolonged the mean animal survival time by 30% compared to the untreated 
control.  At the therapeutic dose, the targeted NP showed little local and systemic 
immunotoxicity and did not decrease the body weight or damage the major organs. 
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5.1 INTRODUCTION 
The lung is a common location of secondary tumor that metastasizes from the primary source 
tumor [79-82].    To date, when pulmonary metastasis are diagnosed, aggressive surgical 
resection is usually performed for the best chance of long-term cure [79].  Unfortunately, a 
high relapse rate (~70%) results in a low survival rate (30%) even after complete resection 
[79].  Lung metastasis relapse usually occurs during chemotherapy [79], indicating that 
conventional anticancer drugs are no longer effective against the metastasis.  Such a life-
threatening condition urgently needs a new and systemic treatment.   
Among anticancer agents, siRNA draws much attention due to its high specificity, 
high efficiency and low toxicity.  By targeting oncogenes, siRNA can be applied as a 
therapeutic agent in cancer therapy [1]; however, delivery of siRNA remains challenging.  
Despite various delivery carriers for siRNA that have been developed, few successful cases 
have been reported on treating metastatic tumor by systemically delivered siRNA 
[12,24,49,75]. 
Previously, we have shown that our targeted nanoparticle (NP) could deliver 
significant amounts of siRNA (70-80% injected dose/g) into the cytoplasm of a xenograft 
tumor in a nude mouse model, which led to the silencing of EGFR, tumor growth inhibition 
and chemosensitization [8].  To address if the targeted NP can also deliver siRNA to a 
metastatic tumor, we used an established experimental lung metastasis model by i.v. injecting 
the murine melanoma cells (B16F10 cells stably transduced with the luciferase gene) into the 
C57BL/6 mice.  We have performed several feasibility studies, which showed that the 
targeted NP improved the delivery and efficacy of the siRNA [32].  First, the targeted NP 
showed an enhanced delivery of cy3-siRNA into the metastatic nodules.  The luciferase gene 
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in the metastatic nodules could be effectively silenced by anti-luciferase siRNA formulated 
in the targeted NP; approximately 70-80% luciferase activity was silenced by a single i.v. 
injection (0.15 mg/kg) [32].  ED50 was only 0.075 mg/kg.  The significantly improved 
primary and metastatic tumor delivery was likely due to the high PEGylation (10.6 mol%) on 
the NP surface, which contained a supported lipid bilayer stabilized by a charge-charge 
interaction. The 10.6 mol% coating of PEG on the NP surface provided full protection and 
improved the pharmacokinetics of which, leading to enhanced RNAi activity. The data 
reported in the Chaper 2, 3 and 4 suggest that the targeted NP formulation may be used for 
the treatment of lung metastasis. 
Combination treatment with three different siRNA sequences (MDM2, c-myc and 
VEGF) has been shown to have a synergistic antiproliferation effect on the B16 cells [48].  
Therefore, we used the combined sequences (MDM2: c-myc: VEGF = 1:1:1, weight ratio) 
for the therapeutic studies.   
5.2 MATERIALS AND METHODS 
5.2.1 Materials  
DOTAP, cholesterol, and DSPE-PEG2000 were obtained from Avanti Polar Lipids, Inc. 
(Alabaster, AL).  Protamine sulfate (fraction X from salmon) and calf thymus DNA (for 
hybridization, phenol-chloroform extracted and ethanol precipitated) were purchased from 
Sigma-Aldrich (St. Louis, MO).  DSPE-PEG2000-anisamide (DSPE-PEG-AA) was 
synthesized in our lab using the methods described previously [53]. 
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B16F10 cells, sigma receptor positive [76] and commonly used for establishing an 
experimental lung metastasis model [32], were used in the study.  The cells were obtained 
from American Type Culture Collection and stably transduced with GL3 firefly luciferase 
gene using a retroviral vector in Dr. Pilar Blancafort’s lab at the University of North Carolina 
at Chapel Hill (UNC).  The cells were maintained in DMEM medium (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA).   
Primary antibodies (mouse monoclonal antibodies against mouse MDM2, c-myc, 
luciferase, β-actin and rabbit polyclonal antibodies against VEGF) and secondary antibodies 
conjugated with horse reddish peroxidase (HRP) (goat anti-mouse IgG-HRP and goat anti-
rabbit IgG-HRP) were purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). 
5.2.2 siRNA   
MDM2 siRNA (target sequence 5’ GCUUCGGAACAAGAGACUC 3’), c-myc siRNA 
(target sequence 5’ GAACAUCAUCAUCCAGGAC 3’), VEGF siRNA (target sequence 5’ 
CGAUGAAGCCCUGGAGUGC 3’), and control siRNA (target sequence: 5’-
AATTCTCCGAACGTGTCACGT-3’) were purchased from Dharmacon (Lafayette, CO) in 
deprotected, desalted, annealed form.  The sequences were adopted from the literature 
[48,67].   
5.2.3 Experimental animals   
Female C57BL/6 mice of age 6-7 week (16-18 g) were purchased from Charles River 
Laboratories (Wilmington, MA).  All work performed on animals was in accordance with 
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and approved by the IACUC committee at UNC.  Murine model of lung metastasis was 
established by i.v. injection of 2×105 B16F10 cells into the C57BL6 mice.  
5.2.4 Preparation of siRNA containing NP   
NP were prepared as previously described in the Chapter 2.  Each component (siRNA, calf 
thymus DNA, protamine, cationic liposome) of the formulation was dissolved or prepared in 
the cloning grade water with non-detectable endotoxin (Sigma-Aldrich, St. Louis, MO).  The 
solution or suspension was then sterile filtered, and the formulations were prepared in the 
laminar flow hood using autoclaved tubes and pipette tips.  The characteristics of the 
formulations were similar to the one reported earlier [32]. 
5.2.5 In vitro gene silencing study 
B16F10 cells (5 × 104 cells/2 ml/well) were seeded into the 6-well plates 20 h before 
experiments.  Cells were treated with different formulations at a concentration of 100 nM for 
total siRNA (MDM2: c-myc: VEFG = 1:1:1, weight ratio) in 10% FBS containing medium at 
37 °C for 48 h.  Cells were washed three times with PBS and fixed with cold acetone for 10 
min.  Immunostaining was then performed according to the method described in 5.2.6.  
Nuclei were counterstained with methylgreen. 
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5.2.6 In vivo gene silencing study 
Tumor bearing mice were given i.v. injections of total siRNA (MDM2: c-myc: VEFG = 
1:1:1, weight ratio) at the dose of 0.45 mg/kg formulated in PBS, the non-targeted NP or the 
targeted NP on day 10 and 11.  One day after the second injection, mice were euthanized and 
the tumor loaded lungs were collected for the preparation of paraffin embedded sections (5 
μm thick).    MDM2, c-myc and VEGF expression in the sections were examined by 
immunohistochemistry using the antibodies with the kit (DakoCytomation Envision + Dual 
Link System-HRP (DAB+), DakoCytomation, Carpinteria, CA) by following the product 
protocol.  Nuclei were counterstained by hematoxylin and samples were imaged with a 
Nikon phase contrast light microscope.  Total protein (10 μg) isolated from the tumor loaded 
lung was resolved on a polyacrylamide/SDS gel and then transferred to a polyvinylidene 
difluoride membrane.  The membranes were blocked with 5% non-fat milk in PBS for 1 h 
and then incubated overnight with primary antibody at 4 ◦C. After washing the membrane 
with TBS (1% Tween 20 in PBS) five times, the membrane was incubated with the HRP 
conjugated secondary antibody for 1 h. The peroxidase activity associated with the protein 
bands was detected by enhanced chemiluminescence using ECL plus (GE Health Care, 
Buckinghamshire, UK) followed by autoradiography. 
5.2.7 In vivo metastasis inhibition study and survival analysis 
Tumor bearing mice were given i.v. injections of total siRNA (MDM2: c-myc: VEFG = 
1:1:1, weight ratio) at the dose of 0.45 mg/kg formulated in PBS, the non-targeted NP or the 
targeted NP on day 10 and 11.  Control siRNA formulated in the targeted NP was also 
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prepared as a negative control.  Mice were euthanized and the tumor loaded lungs were 
collected on day 17.  One lobe of the lung was analyzed for the luciferase activity to quantify 
the lung metastasis nodules.  The lobe was homogenized in 1 ml of the lysis buffer (0.05% 
Triton X-100 and 2 mM EDTA in 0.1 M Tris-HCl) followed by centrifugation at 5,000 rpm 
for 5 min.  Ten μl of the supernatant was mixed with 100 μl luciferase substrate (Luciferase 
Assay System, Promega Co., Madison, WI) and the luciferase activity was measured by a 
plate reader (PLATE CHAMELEON Multilabel Detection Platform, Bioscan Inc., 
Washington, DC).  The rest of the lung was fixed in 3.6% formalin solution overnight and 
imaged.  The fixed lung was processed for paraffin sections followed by H&E staining.  For 
survival analysis study, tumor bearing mice were treated on day 10, 11, 17 and 18.  Mice 
were euthanized when suffered from weight loss greater than 10% or showed ruffled fur. 
5.2.8 Cytokine induction assay 
The C57BL/6 mice were i.v. injected with siRNA (MDM2: c-myc: VEGF = 1:1:1) 
formulated in the targeted NP at various doses and the serum cytokine level was determined 
by the method described previously [8]. 
5.2.9 Local cytokine production analysis.   
Tumor bearing mice were given i.v. injections of siRNA (MDM2: c-myc: VEFG = 1:1:1, 
weight ratio) in different formulations on day 10 at the dose of 0.45 mg/kg.  Two h later, 
mice were sacrificed and the lungs were collected.  The lung was homogenized in 300 μl 
lysis buffer (0.05% Triton X-100 and 2 mM EDTA in 0.1 M Tris-HCl), followed by 
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centrifugation at 10,000 rpm for 20 min.  The supernatant was collected for the assay of the 
cytokines by the ELISA method as described previously [8]. 
5.2.10 Quantitative RT-PCR 
2X105 B16F10 cells per well were seeded in 6-well plates (Corning Inc., Corning, NY) 20 h 
before the experiment. Cells were treated with different formulations at a concentration of 
33.3 nM for single siRNA or 100 nM for combined siRNA (c-myc: MDM2: VEGF = 1:1:1, 
weight ratio) formulated in the targeted NP at 37oC for 12 h. Total RNA were extracted with 
the RNeasy® Mini Kit (Qiagen, Valencia, CA) by following the manufacturer protocol. 
cDNA was then prepared in the presence of reverse transcriptase (Promega, Madison, WI). 
The mRNA levels were determined by an ABI PRISM HT7900 sequence detection system 
(Applied Biosystems, Foster City, CA) as described previously [48].  The primer pairs for 
detecting the mRNA are listed as Table 5.1. 
 
Table 5.1 Primer sequences for qRT-PCR 
Gene Primer sequences References 
Mouse 
MDM2 
Forward 5’ CTC TGG ACT CGG AAG ATT ACA GCC 3’ 
Reverse 5’ CCT GTC TGA TAG ACT GTG ACC CG 3’ 
[83] 
Mouse 
VEGF 
Forward 5’ GGA GAT CCT TCG AGG AGC ACT T 3’ 
Reverse 5’ GGC GAT TTA GCA GCA GAT ATA AGA A 3’ 
[84] 
Mouse  
c-myc 
Forward 5’ CCC CTG GTG CTC CAT GAG 3’ 
Reverse 5’ TCC TCC TCA GAG TCG C 3’ 
[48] 
Mouse 
GAPDH 
Forward 5’ TTC ACC ACC ATG GAG AAG GC 3’ 
Reverse 5’ GGC ATG GAC TGT GGT CAT GA 3’ 
[48] 
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5.2.11 Toxicity assay.   
Tumor bearing mice were given i.v. injections of siRNA (MDM2: c-myc: VEFG = 1:1:1, 
weight ratio) in different formulations on day 10 and 11 at the dose of 0.45 mg/kg.  The body 
weight of the mice was monitored during the treatment.  One day after the second injection, 
the mice were killed and the major organs (heart, lung, liver, spleen and kidney) were 
collected, sectioned, H&E stained and imaged. 
5.2.12 Statistical analysis 
Data are presented as the mean ± SD.  The statistical significance was determined by using 
one-way ANOVA.  The animal survival data were analyzed by the Kaplan-Meier survival 
analysis.  P values of <0.05 were considered significant. 
5.3 RESULTS 
5.3.1 In vivo gene silencing study 
We encapsulated the combined siRNA sequences into different formulations, treated the lung 
metastasis bearing mice on day 10 and 11 with two consecutive i.v. injections (dose = 0.45 
mg/kg) and examined the gene silencing activities by immunohistochemistry (figure 5.1) and 
Western blotting (figure 5.2).  As shown in figure 5.1, only siRNA formulated in the 
targeted NP simultaneously silenced MDM2, c-myc and VEGF in the B16F10 lung 
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metastasis (figure 5.1).  The Western blotting data (figure 5.2) confirmed the observation in 
the immunohistochemical analysis. 
 
Figure 5.1 Immunohistochemical analysis on the lung metastasis. 
Immunohistochemical staining of MDM2, c-myc and VEGF in the B16F10 lung metastatic nodules after 
treatment with siRNA in different formulations.  Magnification = 100x. 
 
 
 
 
Figure 5.2 Western blot analysis on the tumor loaded lung. 
Western blot analysis of MDM2, c-myc and VEGF in the B16F10 tumor loaded lung after treatment with 
siRNA in different formulations. 
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5.3.2 In vivo antitumor/antimetastasis study 
To evaluate the therapeutic outcomes, we initiated two consecutive injections of siRNA (0.45 
mg/kg, MDM2: c-myc: VEGF = 1:1:1, weight ratio) in different formulations 10 days after 
i.v. injection of B16F10 cells, which were stably transduced with a luciferase gene.  As 
shown in figure 5.3a, metastasis nodules were significantly reduced in the lung collected 
from the mice treated with siRNA formulated in the targeted NP.  Other control treatments, 
including free siRNA, siRNA in the non-targeted NP and control siRNA in the targeted NP, 
had very little therapeutic effect (figure 5.3a).  The H&E stained tissue sections also showed 
that the lung treated by siRNA in the targeted NP only had a few small nodules, and most of 
the lung was free of tumor (figure 5.3b).  However, metastasis nodules occupied most of the 
lung when mice were given with other control treatments (figure 5.3b).  To quantify the 
B16F10 nodules in the lung, we collected one lobe of the excised lung and assayed for the 
luciferase activity.  As indicated in figure 5.3c, siRNA in the targeted NP significantly 
reduced the tumor load to 20-30% compared to the untreated control (p<0.01), while other 
control treatments showed no significant effect.  The therapeutic outcome was also analyzed 
by animal survival (figure 5.3d).  On day 23, the survival rates for untreated control or mice 
treated with free siRNA, siRNA in the non-targeted NP, siRNA in the targeted NP and 
control siRNA in the targeted NP were 0%, 0% 50%, 90%, and 40%, respectively (figure 
5.3d), and the mean survival time for which were 22, 22, 23.5, 28 and 22.5 d, respectively.  
Only siRNA in non-targeted NP or targeted NP significantly improved the animal survival 
compared to the free siRNA formulation (p<0.05).  Control siRNA in the targeted NP did not 
improve the animal survival compared to the free siRNA (p>0.05).  Although 2 injections of 
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siRNA in the non-targeted NP did not reduce the tumor metastasis (figure 5.3a, b, c), 4 
injections of the same significantly improved the animal survival (figure 5.3d). 
5.3.3 Toxicity study 
At the therapeutic dose (0.45 mg/kg), the targeted NP did not induce significant production 
of all analyzed cytokines, including IL6, IL12, TNF and IFN-α (figure 5.4).  Even after two 
consecutive injections, the IL6 and IL12 levels were not significantly elevated (data not 
shown).  However, when the dose was increased, the inflammatory toxicity was significantly 
enhanced (figure 5.4), although moderate.  At the therapeutic dose, no formulations elevated 
the cytokine production in the lung (figure 5.5a).  Additionally, the body weight did not 
significantly decrease during the treatment at the therapeutic dose (figure 5.5b).  The 
targeted NP formulation did not damage the major organs (heart, liver, spleen, lung and 
kidney) examined by the tissue section and H&E staining (figure 5.6). 
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Figure 5.3 Anti-metastasis efficacy of different siRNA formulations. 
(a) Images of lungs excised from the tumor bearing mice on day 17 after two consecutive treatments.  (b) 
Photographs of the H&E stained tissue sections processed from the excised lungs.  Magnification = 40x.  (c) 
Luciferase activity in the tumor loaded lungs on day 17 after two consecutive i.v. injections of siRNA in 
different formulations on day 10 and 11.  n = 4 – 9.  *** indicates p<0.0001 compared to the siRNA in PBS 
formulation.  Formulations from left to right: untreated control (black), siRNA in PBS (red), siRNA in non-
targeted NP (green), siRNA in targeted NP (purple), control siRNA in targeted NP (blue). (d) Survival analysis 
of B16F10 lung metastasis bearing mice.  Tumor bearing mice were i.v. injected with different siRNA 
formulations on day 10, 11, 17 and 18.  n = 10.  * indicates p< 0.05, *** indicates p<0.0001 compared to the 
siRNA in PBS formulation.  Formulations: untreated control (black), siRNA in PBS (red), siRNA in non-
targeted NP (green), siRNA in targeted NP (purple), control siRNA in targeted NP (blue). 
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Figure 5.4 Serum cytokine analysis. 
Serum cytokine levels of C57BL/6 mice 2 h after receiving i.v. injections of siRNA in targeted NP at different 
doses.  Data = mean ± SD, n = 4. * indicates p<0.05; ** indicates p<0.01 compared to the untreated control. 
 
 
 
 
 
Figure 5.5 Toxicity assay. 
(a) Cytokine production in the tumor loaded lung of the tumor bearing mice 2 h after the i.v. injection of siRNA 
in different formulations (dose = 0.45 mg/kg).  Data = mean + SD, n = 3-4. (b) Mouse body weight one day 
after the second treatment of siRNA in different formulations.  Data = mean + SD, n = 3-4. 
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Figure 5.6 Tissue section examination. 
Microscopic examination of the H&E stained tissue sections collected from the untreated control mouse or the 
targeted NP treated mouse.  Magnification = 200x 
5.4 DISCUSSION 
To improve the antitumor/antimetastasis effect, we used combined siRNA sequences 
(MDM2: c-myc: VEGF = 1:1:1, weight ratio) to attack multiple oncogene pathways.  MDM2 
is an inactivator for p53 [85] and c-myc serves as an activated transcription factor, which 
promotes cell proliferation [86].  VEGF is a growth factor secreted by the tumor and 
mediates angiogenesis and metastasis [87].  According to the literature, simultaneous silence 
of these oncogenes by siRNA resulted in enhanced antiproliferation on the B16 cells [48].  
Recently, it was demonstrated that combined delivery of different siRNA sequences resulted 
in siRNA competition for incorporation into RISC (RNA-induced silencning complex) and 
reduced RNAi efficacy [26,88].  To determine if combination of the three siRNA sequences 
interferes with the gene silencing activity of each sequence, we employed qRT-PCR method 
to quantify the RNAi activity of single sequence and pooled sequences delivered by the 
targeted NP.  Indeed, we found the sequence competition effect, as the pooled siRNA 
formulation showed significantly reduced gene silencing activity on the c-myc and MDM2 
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genes but not on the VEGF gene compared to the single siRNA formulations (figure 5.7). 
However, the competition effect was moderate and significant gene knock-down (45-85%) 
was observed in all genes when 100 nM pooled siRNA was used.  The data suggest that 
combined delivery of these three sequences may be acceptable.  We have also checked the 
RNAi activity in protein level by immunocytochemistry.  As shown in figure 5.8, siRNA in 
the targeted NP silenced MDM2, c-myc and VEGF in the B16F10 cells at the concentration 
of 100 nM (total siRNA), while other control treatments, including free siRNA, siRNA in 
non-targeted NP and control siRNA in targeted NP showed little effect.  This resulted in an 
enhanced antiproliferation effect on the B16f10 cells by the targeted NP (data not shown).  
Both the in vitro and in vivo gene silencing results (figure 5.1, 5.2 and 5.8) showed that the 
gene silencing activity was highly formulation and siRNA sequence dependent, suggesting 
that only sufficient delivery of the correct sequences of siRNA resulted in significant activity.  
The antitumor activities of different formulations were highly correlated to their RNAi 
activities, in which only the targeted NP significantly reduced the tumor load (figure 5.3a, b, 
c). 
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Figure 5.7 Relative mRNA level in the B16F10 cells 12 h after treatment with single or combined 
sequences formulated in the targeted NP.   
Data = mean + SD, n = 4. * indicates p<0.05 
 
 
 
Figure 5.8 Immunocytochemical analysis on the B16F10 cells. 
Immunocytochemical staining of MDM2, c-myc and VEGF in the B16F10 cells after treatment with siRNA in 
different formulations (from left to right: untreated control, siRNA in PBS, siRNA in non-targeted NP, siRNA 
in targeted NP, control siRNA in targeted NP).  Total siRNA concentration = 100 nM.  Magnification = 100x. 
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Although 2 injections of siRNA in the non-targeted NP did not reduce the tumor load 
in the lung (figure 5.3a, b, c), 4 injections of the same significantly improved the animal 
survival (figure 5.3d, p<0.05).  The results suggest that multiple dosing may compensate the 
poor delivery of the non-targeted formulation. However, the survival prolongation of the 
non-targeted NP was moderate, although statistically significant.  Targeted NP, on the other 
hand, with superior delivery efficiency for metastasis [32] not only significantly reduced the 
tumor load in the lung (figure 5.3a, b, c), but also prolonged the survival by approximately 
30% (figure 5.3d).  Targeted NP showed significantly improved therapeutic effects 
compared to any other siRNA formulations (figure 5.3).  While unlikely, it is possible that 
the off-target effects of the combinatorial siRNA contributed to the in vivo reduction of 
tumor load.  The off-target effect of siRNA causing non-specific gene down-regulation was 
first reported by Scacheri et al. [89].  It is speculated that partial complementary sequence of 
the siRNA matches to the off-target genes, and the genes are silenced via the micro-RNA 
mechanism.  This is particular a concern when multiple siRNA sequences are used.  Whether 
the off-target effects of the siRNA contributed to the antitumor effect of our formulation is 
not clear at the present time.  However, the primary goal of this research is to develop a 
delivery system, the off-target effects contributing the antitumor activity will be studied and 
reported later.  Additionally, the toxicity study showed that the targeted NP was safe at the 
therapeutic dose (figure 5.4, 5.5, 5.6). 
To summarize, with the improved delivery of siRNA by the targeted NP [32], the 
corresponding oncogenes were simultaneously silenced, mass of lung metastasis was greatly 
reduced and animal survival was significantly prolonged with a relatively low and non-toxic 
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dose (0.45 mg/kg).  Thus, we conclude that siRNA formulated in the targeted NP has the 
potential to become a useful method for cancer therapy. 
6.0  DISCUSSION 
6.1 SUMMARY OF RESEARCH RESULTS AND FUTURE PLANS 
It is known that sufficient modification on the nanoparticle (NP) surface with an inert 
hydrophilic polymer is prerequisite for prolonged in vivo circulation time and the enhanced 
permeability and retention (EPR) effect for tumor delivery.  With a supported lipid bilayer 
structure, the LPD NP could accomodate an increased degree of PEGylation compared to the 
conventional liposomes with a regular lipid bilayer.  We have shown that approximately 10.6 
mol% of the outer leaflet of the supported lipid bilayer was modified with DSPE-PEG, 
resulting in complete surface charge shielding and reduction in the reticuloendothelial uptake 
in the isolated liver model (Chapter 2).  This highly PEGylated NP formulation delivered a 
high dose of siRNA (70-80% injected dose/g) to the s.c. tumor and induced significant RNAi 
and antitumor effects.  The high tumor accumulation effect was primarily due to an improved 
EPR effect, since the targeting ligand (anisamide) containing formulation did not show 
further enhancement of tumor delivery.  However, the targeted NP had increased intracellular 
delivery compared to the non-targeted NP (Chapter 3).  The targeted NP also showed 
improved delivery to the lung metastasis, resulting in significant gene silencing, tumor load 
reduction and survival prolongation (Chapter 4 and 5). 
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Our future plan is to further optimize the formulation to enhance the antitumor effect 
and make the formulation suitable for human use.  First, in the LPD formulation, we use a 
foreign DNA, calf thymus DNA, to improve the complex formation.  However, the concerns 
of hypersensitivity, unexpected immune responses and the expression of foreign proteins in 
the patients receiving the formulation may prevent clinical use of the formulation.  We plan 
to employ a biocompatible and negatively charged polymer, such as heparin and hyaluronic 
acid, to replace the calf thymus DNA to develop a new formulation.  Since the LPD is 
formed by the charge-charge interaction, we predict that this new approach has a good 
chance of success.  In addition, both heparin and hyaluronic acid have been approved by the 
US FDA for human use.  However, intensive toxicity studies need to be done.  Second, in the 
preliminary study (Chen and Huang, unpublished data), our lab has found that the DOTAP 
used in the formulation transiently activated some survival signals in the tumor cells, 
including p-ERK and survivin, which may compromise the antitumor effect of the 
formulation.  We plan to synthesize a new class of cationic lipids that show higher delivery 
efficiency but no activation on survival pathways in the tumor cells.  This may greatly 
enhance the antitumor activity of the new formulation.  Third, the anisamide ligand is 
employed in the LPD for increasing the intracellular delivery into the sigma receptor 
expressing cells.  However, sigma receptor is only expressed in certain type of human 
tumors.  To further increase the spectrum of our formulation, we will have to develop other 
types of tumor targeting ligands.  A small molecule ligand with high specificity is preferred 
due to the cost-effectiveness concern and low immunogenecity.  A possible direction is to 
develop a ligand that targets angiogenic endothelial cells to improve the anti-angiogenesis 
and antitumor effect.  Fourth, to facilitate the endosomal escape of the formulation, we plan 
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to synthesize and incorporate a diblock polypeptide [poly(histidine)-poly(arginine)] in the 
formulation.  The protamine will be totally or partially replaced with the polypeptide in the 
new formulation.  The poly-arginine segment will condense the nucleic acid into a nano-
complex, while the poly-histidine can induce the proton sponge effect in the endosome to 
improve the release and bioavailability of siRNA. 
6.2 SUPPLEMENTARY INFORMATION 
6.2.1 Formulation 
The LPD formulation was prepared in a self-assembling process upon charge-charge 
interaction.  The process must be done in a diluted and salt-free condition to prevent 
aggregation.  In this dissertation research, we prepared the formulation in the cloning water.  
Several concerns may be raised.  First, low osmolarity of the nanoparticle suspension may 
cause transient hemolysis once i.v. administered.  This potential problem can be solved by 
preparing the formulation in a salt-free and isotonic solution, such as 5% dextrose.  Second, a 
mouse was given approximately 250-350 μl of the nanoparticle formulations (dose = 1.2 
mg/kg), contributing to 18-20% of the blood volume of a mouse.  Ideally, 10% of the blood 
volume is the maximum for i.v. administration.  High volume injection may alter the 
physiology of the mouse.  However, the nanoparticle must be prepared in a diluted condition 
to avoid aggregation and thus, a large volume is required to achieve the therapeutic dose.  In 
future clinical practice, the LPD formulation can be given by slow i.v. infusion, which was 
used in the clinical trials for the SNALP formulation developed by the Protiva 
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Pharmaceuticals.  For an 80 kg-patient, 0.4-1.2 L of the LPD formulation will be needed 
(0.45-1.2 mg/kg).  Third, the pH of the LPD formulations was 5, which is tolerable for i.v. 
injection.  Fourth, endotoxin has been known to trigger immunological responses in the host 
and free of endotoxin is a basic requirement for parenteral drugs used in human and animals.  
The upper limit for endotoxin in parenteral drugs generally acceptable to the U.S. Food and 
Drug Administration (FDA) is 5 EU/kg.  For a 20 g-mouse, the tolerated endotoxin dose is 
0.1 EU.  The endotoxin level in the LPD formulation was 0.46 EU/ml and approximately 
0.15 EU was injected into a 20 g-mouse at the dose of 1.2 mg siRNA/kg, which is slightly 
higher than the upper limit.  Although the formulation was prepared with the cloning water 
(endotoxin free), the tips and eppendorff tubes were not properly treated to remove pyrogens, 
leaving the final suspension potentially contaminated with a low amount of endotoxin.  To 
address this issue, the formulation must be prepared in an endotoxin free condition and the 
final product must be checked for its endotoxin level.  The interference from the excepients 
on measurement of endotoxin should also be studied. 
Another issue for the formulation is stability.  We found precipitates in the 
formulation after storage at 4oC for 1 week.  The naked LPD has been shown to be stable in 
the same condition for 4 weeks.  The DSPE-PEG micelle, on the other hand, precipitated 
during the storage at 4oC.  Therefore, it is likely that the instability of the PEGylated LPD 
formulation was due to the addition of DSPE-PEG micelle.  It is anticipated that the purified 
formulation (by gel filtration) will have an improved stability.  However, the high degree of 
dilution after purification is a critical disadvantage.  Fortunately, the nanoparticles were 
prepared by a quick self-assembling procedure.  With these, we decided to prepare the 
formulations freshly and used them without purification. Alternatively, LPD can be 
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lyophilized for long term storage [35]. We expect that the PEGylated LPD can also be 
stabilized the same way. 
6.2.2 Pharmacokinetic study 
6.2.2.1 Extraction recovery and the dose recovery from the major organs 
The extraction recoveries of the free FAM-siRNA and FAM-siRNA in nanoparticles from 
the mouse serum were 98% and 48%, respectively.  The serum concentration of the FAM-
siRNA was determined by dividing the measured value by the extraction recovery.  To 
determine the tissue accumulation of FAM-siRNA, a dose calibration curve for each organ 
was obtained by spiking known amounts of free FAM-siRNA or FAM-siRNA in 
nanoparticles in the tissue lysates.  The extraction recoveries for the nanoparticle formulation 
in the organs is assumed to be 48% (not determined), which limited the detection range and 
led to the failure of detecting low amounts of the dose distributed in organs, such as the 
kidney, spleen and heart.  This may contribute to the relatively low total dose recovery from 
the major organs (~60%).  The loss of the dose in the tail, urine, bile or by the degradation in 
the liver may also contribute to the low recovery.  
6.2.2.2 Can the high tumor uptake of the FAM-siRNA in nanoparticles be model 
dependent? 
 
Four h after the i.v. administration of the FAM-siRNA in the nanoparticles, the dose 
remaining in the blood decreased to 10% injected dose (ID) in the tumor free mice.  Majority 
of the siRNA distributed to the liver in the tumor free nude mice (figure 6.1, upper panel).  
Relatively speaking, the nanoparticle formulation was not very stealth.  However, the 
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formulation delivered 70-80% ID into the NCI-H460 xenograft tumor.  One possible 
explanation is that the nanoparticle had a high tendency to extravasate to the highly 
vascularized tissues, such as the liver and tumor.  In the tumor free mice, the liver 
contributed majority of the uptake.  In the tumor-bearing mice, the tumor competed the 
uptake of the formulation with the liver, resulting in reduced liver uptake.   To address if the 
high tumor uptake of the formulation was model dependent, we performed the tissue 
distribution study in two other tumor models, including TC-1 tumor in C57BL/6 mice and 
CT-26 tumor in Balb/c mice.  As shown in figure 6.1 (lower panel), both the liver and tumor 
contributed significant uptake of the nanoparticle formulation in both models, indicating that 
some unique features of the NCI-H460 model may contribute to the high tumor uptake.  
Nevertheless, the nanoparticle formulation delivered a significant amount of siRNA to the 
tumor in both models.  Quantitative tissue distribution studies will be performed to confirm 
the observation. 
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Figure 6.1 Tissue distribution of fluorescently labeled siRNA in different animal models. 
Upper panel: tissue distribution in tumor free nude mice.  Lower panel: tissue distribution in tumor-bearing 
mice.  Tissues were analyzed 4 h after i.v. injection by the Xenogen IVISTM imaging system.  
 
6.3 FURTHER DIRECTIONS 
The key success of the research is based on the existence of the supported lipid bilayer on 
surface of the NP.  With the supported bilayer, a high degree of PEGylation can be achieved 
to provide full protection for the NP, leading to improved pharmacokinetics and tumor 
targeting.  NP containing a supported bilayer can be designed by a variety of methods.  The 
key point is to employ an extra force to stabilize one or both leaflet of the bilayer, such as 
electrostatic force or covalent bonding.  Here, two strategies are proposed to prepare a 
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nanoparticle formulation with a supported bilayer for a hydrophilic drug.  In both cases, the 
supported bilayer is stabilized with covalent bonds.  We propose to utilize the amphipathic 
polymer to prepare the nanoparticles (figure 6.2).  Amphipathic polymer contains a 
backbone polymer structure with an alternative arrangement of hydrophilic and hydrophobic 
side chains.  The polymer can be used to prepare water in oil nano-emulsion with a water 
soluble drug in the aqueous phase.  Organic solvent that is immiscible with water and volatile 
will be used for the oil phase, such as chloroform and dichloromethane.  Then, the reverse-
phase evaporation method will be performed to remove the solvent and coat the W/O nano-
emulsion with another layer of the polymer [90]; and thus, the nanoparticle with a supported 
bilayer is obtained.  
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Figure 6.2 Proposed method for preparing a nanoparticle with a supported bilayer by amphipathic 
polymer 
 
Another approach involves using a lipid-like surfactant with a polymerizable head 
group to prepare the nano-emulsion encapsulating a water soluble drug in the aqueous phase 
(figure 6.3).  Then, the surfactants surrounding the aqueous phase are polymerized by the 
addition of an initiator.  Finally, the reverse-phase evaporation method is used to coat another 
lipid leaflet on the particle and the nanoparticle with a supported bilayer is formed.  It is 
noted that only the inner leaflet of the bilayer is cross-linked and the outer leaflet is of high 
fluidity for post-insertion of DSPE-PEG. 
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Figure 6.3 Preparation of a nanoparticle with a supported bilayer by the polymerization method 
 
In both case, the hydrophilic group of the lipid or polymer in the outer leaflet is 
preferred to be positively charged for facilitating drug release from the endosome.  As 
discussed in the Chapter 1, formation of charge complex between the cationic lipid and the 
anionic endosomal lipid may lead to local dehydration and destabilization of the endosomal 
membrane [18], resulting in the release of encapsulated drugs into the cytoplasm. 
Another possible approach is to use a lipid with cross-linkable acyl chains to prepare 
the liposomes and then trigger the cross-linking reaction for the preparation of a supported 
bilayer.  However, the cross-linking reaction in the interface is usually not complete and hard 
to control, leaving the lipid membrane a mixture of cross-linked lipid grafts of low fluidity 
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and single lipids with high fluidity.  This results in increased membrane permeability and 
drug release. 
6.4 ENDING REMARKS 
siRNA based gene therapy has enjoyed a great success over the past few years.  The success 
of siRNA is mainly due to three reasons.  First, siRNA can be chemically synthesized in the 
pharmaceutical grade and can be chemically modified to have improved pharmacokinetics.  
Second, the fast advance of siRNA delivery technology is based on the foundation of 
experiences from plasmid DNA delivery accumulating since 1980s.  Third, efficient nuclear 
delivery that has prevented the success of gene therapy is not required for siRNA.   
The first clinical trial for siRNA has been successfully completed in 2005. The 
product, sirna-027, was developed by the Sirna Therapeutics, which was acquired by Merck 
for approximately $1.1 billion in 2006.  This chemically modified siRNA is designed for 
treating macular degeneration by silencing VEGFR in the eyes.  The results in the trial have 
encouraged Merck to move sirna-027 forward into phase II clinical trials.  In addition to 
many small biotech companies devoting their research on siRNA based therapy, big 
pharmaceutical companies, such as Merck, Novartis, Roche, Pfizer, AstraZeneca and 
GlaxoSmithKline, have also put significant investments on this technology.  Therefore, an 
increased number of clinical trials for siRNA products are to come and the bright future of 
siRNA is expected.     
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APPENDIX A 
THEORY OF DYNAMIC LIGHT SCATTERING FOR PARTICLE SIZE ANALYSIS 
The Nicomp Particle Size Analyzer uses Dynamic Light Scattering (DLS) to obtain the 
particle size distribution for samples with particles ranging from 1 nm to 5 microns. Through 
the use of the proprietary Nicomp analysis algortihm, the instrument can analyze multi-
modal distributions with high resolution and reproducibility. 
DLS, also known as Photon Correlation Spectroscopy (PCS), works by first 
measuring the scattered light intensity at one angle, which tends to decay with time 
periodically. These fluctuations in the intensity are caused by the constant moving of the 
particle brought on by Brownian motion. Larger particles tend to move more slowly. The 
time-dependent fluctuations in the scattered light are measured by a fast photon counter. The 
fluctuations are directly related to the rate of diffusion of the particle. Therefore, the 
fluctuations can be analyzed to determine a hydrodynamic radius of the particles. 
The fluctuations are quantified via a second order correlation function measured by 
the instrument. The second order correlation function is given by  
2
)2(
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)()(
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tItI
g
ττ +=                                                                                                (1) 
where I(t) is the intensity of the scattered light at time t, and the brackets indicate averaging 
over all t. The correlation function depends on the delay τ, the amount that a duplicate 
intensity trace is shifted from the original before the averaging is performed.  
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The correlation function for a monodisperse sample can be analyzed by the equation:  
)2exp()()2( τβτ Γ−×+= Bg                                                                                       (2) 
where B is the baseline of the correlation function at infinite delay, β is the correlation 
function amplitude at zero delay, and Γ is the decay rate.  The software uses a nonlinear least 
squares fitting algorithm to fit the measured correlation function to equation 2 to obtain the 
decay rate Γ. Then, Γ can be converted to the diffusion constant (D) of the particle via the 
equation:  
2q
D Γ=                                                                                                                         (3) 
here, q is the magnitude of the scattering vector, and is given by: 
            )2/sin(4 θλ
πnq =                                                                                                         (4) 
where n is the solvent index of refraction, λ is the vacuum wavelength of the incident light, 
and θ is the scattering angle. 
Finally, the hydrodynamic radius (rk) of a diffusing spherical particle can be obtained 
via the Stokes-Einstein equation:  
D
kTrk πη6=                                                                                                                  (5) 
where k is Boltzmann's constant, T is the temperature in K, and η is the solvent viscosity. 
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APPENDIX B 
THEORY OF ZETA POTENTIAL MEASUREMENT 
The ZetaPlus zeta potential analyzer (Brookhaven) calculates the zeta potential by 
determining the electrophoretic mobility and then applying the Henry equation.  The 
electrophoretic mobility is measured by performing an electrophoresis experiment on the 
sample and determining the velocity of the particles. 
What is zeta potential 
The net charge at the particle surface attracts counter ions close to the surface (as shown in 
figure 6.1), resulting in formation of an electrical double layer around each particle. 
The electrical double layer contains two layers, stern layer and diffuse layer.  In the 
stern layer, the ions are strongly bound to the particle surface; while in the diffuse region, the 
ions are less firmly attached.  Within the diffuse layer there is a boundary which the ions and 
particles form a stable entity.  When a particle moves, ions within the boundary move with it, 
but not the ions beyond the boundary.  The boundary is called the shear plane or slipping 
plane.  The potential that exists at this boundary is known as the zeta potential. 
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Figure 6.4 Illustration of the electrical double layer and zeta potential of a negatively charged particle 
Measurement of zeta potential 
When an electric field is applied, charged particles are attracted moving toward the electrode 
of opposite charge.  When equilibrium is reached, the particles move in a constant velocity.  
The velocity of a particle in a given electric filed is referred to as its electrophoretic mobility.  
The zeta potential can be calculated by application of the Henry equation: 
η
ε
3
)(2 kazfUE =                                                                                                             (6) 
z: zeta potential 
UE: electrophoretic mobility 
ε: dielectric constant 
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η: viscosity 
f(ka): Henry’s function. Two values are generally used as approximations for the f(ka) 
determination, either 1.5 or 1.0.  When electrophoretic determinations of zeta potential are 
made in aqueous media and moderate electrolyte concentration, f(ka) is 1.5 (referred to as the 
Smoluchowski approximation, for particles larger than 200 nm).  For small particles in low 
dielectric constant media, f(ka) becomes 1.0 (referred to as the Huckel approximation). 
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APPENDIX C 
SHYH-DAR LI’S PUBLICATION 
Peer-reviewed Papers 
• Shyh-Dar Li and Leaf Huang. Nanoparticles Stabilized with a Supported Bilayer. 
(submitted) 
• Shyh-Dar Li, Sumio Chono, and Leaf Huang. Efficient Oncogene Silencing and 
Metastasis Inhibition via Systemic Delivery of siRNA. Mol Ther (accepted) 
• Shyh-Dar Li, Sumio Chono, and Leaf Huang. Efficient Gene Silencing in Metastatic 
Tumor by siRNA Formulated in Surface-modified Nanoparticles. J Controlled 
Release 126 (1): 77-84, 2008 
• Shyh-Dar Li, Yung-Ching Chen, Michael J. Hackett and Leaf Huang. Targeted 
Delivery of siRNA by Self-assembled Nanoparticles. Mol Ther 16 (1): 163-169, 2008 
• Feng Liu, Demet Sag, Jue Wang, Lisa M Shollenberger, Feilong Niu, Xing Yuan, 
Shyh-Dar Li, Mike Thompson and Paul Monahan. Sine-wave Current for Efficient 
and Safe In Vivo Gene Transfer. Molecular Therapy 15 (10): 1842–1847, 2007 
• Shyh-Dar Li and Leaf Huang. Surface-modified LPD Nanoparticles for Tumor 
Targeting. Ann N Y Acad Sci. 1082:1-8, 2006 
• Shyh-Dar Li and Leaf Huang. Targeted Delivery of Antisense Oligodeoxynucleotide 
and Small Interference RNA into Lung Cancer Cells. Mol Pharm. 3 (5):579-88, 2006 
Review Papers and Perspectives 
• Shyh-Dar Li and Leaf Huang. Non-viral is Superior to Viral Gene Delivery 
(perspective). J Controlled Release 123 (3): 181-183, 2007  
• Shyh-Dar Li and Leaf Huang. Gene Therapy Progress and Prospects: Non-viral Gene 
Therapy by Systemic Delivery (review). Gene Ther. 13(18):1313-9, 2006 
• Shyh-Dar Li and Leaf Huang. Targeted Delivery of siRNA: Lessons from the Recent 
Advances. Current Opinion in Molecular Therapy (under review) 
• Shyh-Dar Li and Leaf Huang. Pharmacokinetics and Biodistribution of 
Nanoparticles. Molecular Pharmaceutics (in preparation) 
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Book Chapter 
• Shyh-Dar Li, Song Li and Leaf Huang. Lipoplex and LPD Nanoparticles for In Vivo 
Gene Delivery. In “Gene Transfer. Delivery and Expression of DNA and RNA”, Eds, 
Friedman, T and Rossi J. Cold Spring Harbor Laboratory Press. Chapter 39, pp 433 – 
438, 2006. 
Conference Abstracts 
• Shyh-Dar Li, Sumio Chono and Leaf Huang. Efficient Gene Silencing in Metastatic 
Tumors by Systemically Delivered siRNA. NCI Alliance Meeting. Chapel Hill, NC, 
USA, 2007 
• Shyh-Dar Li and Leaf Huang. Targeted Delivery of siRNA for Lung Cancer and 
Lung Metastases Therapy. AAPS Annual Meeting. San Diego, USA, 2007 (Selected 
for oral and poster presentation in AAPS graduate student symposium in drug 
delivery and pharmaceutical technologies) 
• Shyh-Dar Li and Leaf Huang. Targeted Delivery of Antisense Oligonucleotide and 
siRNA into Lung Cancer Cells. 9th Annual Meeting of American Society of Gene 
Therapy. Baltimore, Maryland, USA. 2006 
• Shyh-Dar Li and Leaf Huang. Tumor Targeted Delivery of siRNA by i.v. injection. 
10th Liposome Research Days Conference, Chapel Hill, NC, USA, 2006 (Selected 
Oral Presentation. Genzyme Pharmaceutics Outstanding Poster Award) 
• Shyh-Dar Li and Leaf Huang. Targeted delivery of antisense oligodeoxynucleotide 
and small interference RNA into lung cancer cells. Ann N Y Acad Sci. Fist 
Oligonucleotide Meeting. NYC, NY 2005 (Invited Speaker) 
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